US20180318289A1 - Treatments for depression and other diseases with a low dose agent - Google Patents
Treatments for depression and other diseases with a low dose agent Download PDFInfo
- Publication number
- US20180318289A1 US20180318289A1 US16/031,662 US201816031662A US2018318289A1 US 20180318289 A1 US20180318289 A1 US 20180318289A1 US 201816031662 A US201816031662 A US 201816031662A US 2018318289 A1 US2018318289 A1 US 2018318289A1
- Authority
- US
- United States
- Prior art keywords
- depression
- naltrexone
- treatment
- patient
- low dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 124
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 26
- 201000010099 disease Diseases 0.000 title abstract description 8
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims abstract description 195
- 229960003086 naltrexone Drugs 0.000 claims abstract description 191
- 238000000034 method Methods 0.000 claims abstract description 153
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims abstract description 50
- 230000002265 prevention Effects 0.000 claims abstract description 17
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 150
- 239000003795 chemical substances by application Substances 0.000 claims description 95
- 229960003638 dopamine Drugs 0.000 claims description 77
- 239000000935 antidepressant agent Substances 0.000 claims description 60
- 208000020401 Depressive disease Diseases 0.000 claims description 55
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims description 53
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims description 53
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 46
- 230000009467 reduction Effects 0.000 claims description 45
- 230000000694 effects Effects 0.000 claims description 42
- 230000004044 response Effects 0.000 claims description 37
- 230000001430 anti-depressive effect Effects 0.000 claims description 34
- 230000003190 augmentative effect Effects 0.000 claims description 31
- 229940005513 antidepressants Drugs 0.000 claims description 29
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims description 25
- 229960004372 aripiprazole Drugs 0.000 claims description 22
- 208000024714 major depressive disease Diseases 0.000 claims description 21
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical class C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 19
- 229960001653 citalopram Drugs 0.000 claims description 16
- 102000005962 receptors Human genes 0.000 claims description 16
- 108020003175 receptors Proteins 0.000 claims description 16
- 239000002552 dosage form Substances 0.000 claims description 15
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 15
- 102000015554 Dopamine receptor Human genes 0.000 claims description 14
- 108050004812 Dopamine receptor Proteins 0.000 claims description 14
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims description 14
- -1 s-citalopram Chemical compound 0.000 claims description 14
- 229960002073 sertraline Drugs 0.000 claims description 14
- 230000003001 depressive effect Effects 0.000 claims description 13
- 229960003089 pramipexole Drugs 0.000 claims description 13
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims description 12
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims description 11
- 229960001058 bupropion Drugs 0.000 claims description 11
- 238000000586 desensitisation Methods 0.000 claims description 11
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 11
- 229960002866 duloxetine Drugs 0.000 claims description 10
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims description 10
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 claims description 9
- 230000002441 reversible effect Effects 0.000 claims description 9
- 229960001879 ropinirole Drugs 0.000 claims description 9
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 8
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 8
- 229960002464 fluoxetine Drugs 0.000 claims description 8
- 229960001800 nefazodone Drugs 0.000 claims description 8
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 8
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 7
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 7
- USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 claims description 7
- 229940005501 dopaminergic agent Drugs 0.000 claims description 7
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 7
- 229960004038 fluvoxamine Drugs 0.000 claims description 7
- SADQVAVFGNTEOD-UHFFFAOYSA-N indalpine Chemical compound C=1NC2=CC=CC=C2C=1CCC1CCNCC1 SADQVAVFGNTEOD-UHFFFAOYSA-N 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 7
- 229960002296 paroxetine Drugs 0.000 claims description 7
- 238000011269 treatment regimen Methods 0.000 claims description 7
- 229960004688 venlafaxine Drugs 0.000 claims description 7
- OYPPVKRFBIWMSX-SXGWCWSVSA-N zimeldine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 claims description 7
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims description 6
- 229960005217 dapoxetine Drugs 0.000 claims description 6
- 229950002473 indalpine Drugs 0.000 claims description 6
- 229960000600 milnacipran Drugs 0.000 claims description 6
- 238000001050 pharmacotherapy Methods 0.000 claims description 6
- 238000011084 recovery Methods 0.000 claims description 6
- 230000000697 serotonin reuptake Effects 0.000 claims description 6
- 229960002791 zimeldine Drugs 0.000 claims description 6
- 239000006186 oral dosage form Substances 0.000 claims description 3
- 239000006203 subcutaneous dosage form Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 abstract description 60
- 208000020925 Bipolar disease Diseases 0.000 abstract description 25
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract description 22
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract description 21
- 208000005793 Restless legs syndrome Diseases 0.000 abstract description 20
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract description 20
- 208000019022 Mood disease Diseases 0.000 abstract description 19
- 208000008589 Obesity Diseases 0.000 abstract description 19
- 208000018737 Parkinson disease Diseases 0.000 abstract description 19
- 235000020824 obesity Nutrition 0.000 abstract description 19
- 239000003887 narcotic antagonist Substances 0.000 abstract description 7
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 abstract description 6
- 239000003401 opiate antagonist Substances 0.000 description 97
- 150000001875 compounds Chemical class 0.000 description 46
- 235000002639 sodium chloride Nutrition 0.000 description 43
- 150000003839 salts Chemical class 0.000 description 38
- 230000000670 limiting effect Effects 0.000 description 20
- 208000035475 disorder Diseases 0.000 description 18
- 239000003814 drug Substances 0.000 description 17
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 17
- 238000009472 formulation Methods 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 10
- 230000036651 mood Effects 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 238000002648 combination therapy Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 229960001344 methylphenidate Drugs 0.000 description 9
- 239000000556 agonist Substances 0.000 description 8
- 238000013270 controlled release Methods 0.000 description 8
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 230000000977 initiatory effect Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 229960004431 quetiapine Drugs 0.000 description 7
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229940025084 amphetamine Drugs 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000003291 dopaminomimetic effect Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 6
- 229940044551 receptor antagonist Drugs 0.000 description 6
- 239000002464 receptor antagonist Substances 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 238000013268 sustained release Methods 0.000 description 6
- 239000012730 sustained-release form Substances 0.000 description 6
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 5
- 208000007415 Anhedonia Diseases 0.000 description 5
- 206010054089 Depressive symptom Diseases 0.000 description 5
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 5
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 5
- 229940047812 adderall Drugs 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 229960001785 mirtazapine Drugs 0.000 description 5
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 5
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 5
- 229960002748 norepinephrine Drugs 0.000 description 5
- 239000004031 partial agonist Substances 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 238000002203 pretreatment Methods 0.000 description 5
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 206010010144 Completed suicide Diseases 0.000 description 4
- 206010012374 Depressed mood Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 description 4
- 229940123257 Opioid receptor antagonist Drugs 0.000 description 4
- 208000028017 Psychotic disease Diseases 0.000 description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 208000014679 binge eating disease Diseases 0.000 description 4
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 4
- 229960002802 bromocriptine Drugs 0.000 description 4
- 238000011260 co-administration Methods 0.000 description 4
- 229960000632 dexamfetamine Drugs 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 4
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000007848 Alcoholism Diseases 0.000 description 3
- 206010011469 Crying Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010026749 Mania Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108090000137 Opioid Receptors Proteins 0.000 description 3
- 102000003840 Opioid Receptors Human genes 0.000 description 3
- 208000026251 Opioid-Related disease Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 201000007930 alcohol dependence Diseases 0.000 description 3
- 229960002430 atomoxetine Drugs 0.000 description 3
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000002825 dopamine reuptake Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 150000004679 hydroxides Chemical class 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VOBHXZCDAVEXEY-JSGCOSHPSA-N lisdexamfetamine Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)CC1=CC=CC=C1 VOBHXZCDAVEXEY-JSGCOSHPSA-N 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YNZFUWZUGRBMHL-UHFFFAOYSA-N 2-[4-[3-(11-benzo[b][1]benzazepinyl)propyl]-1-piperazinyl]ethanol Chemical compound C1CN(CCO)CCN1CCCN1C2=CC=CC=C2C=CC2=CC=CC=C21 YNZFUWZUGRBMHL-UHFFFAOYSA-N 0.000 description 2
- AWFDCTXCTHGORH-HGHGUNKESA-N 6-[4-[(6ar,9r,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carbonyl]piperazin-1-yl]-1-methylpyridin-2-one Chemical class O=C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC(Br)=C(C=34)C2)C1)C)N(CC1)CCN1C1=CC=CC(=O)N1C AWFDCTXCTHGORH-HGHGUNKESA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000013366 Filamin Human genes 0.000 description 2
- 108060002900 Filamin Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 2
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 2
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010062519 Poor quality sleep Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 208000028683 bipolar I disease Diseases 0.000 description 2
- 208000025307 bipolar depression Diseases 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229960001210 brexpiprazole Drugs 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002635 electroconvulsive therapy Methods 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940102213 injectable suspension Drugs 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229960001451 lisdexamfetamine Drugs 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 2
- 229960004127 naloxone Drugs 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000000966 norepinephrine reuptake Effects 0.000 description 2
- 229960001158 nortriptyline Drugs 0.000 description 2
- 201000005040 opiate dependence Diseases 0.000 description 2
- 229960005290 opipramol Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960002431 trimipramine Drugs 0.000 description 2
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229960003740 vilazodone Drugs 0.000 description 2
- SGEGOXDYSFKCPT-UHFFFAOYSA-N vilazodone Chemical compound C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 SGEGOXDYSFKCPT-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 1
- DAWXRFCLWKUCNS-MNTSKLTCSA-N (2s)-2-aminobutanedioic acid;1-phenylpropan-2-amine;hydrate Chemical compound O.OC(=O)[C@@H](N)CC(O)=O.CC(N)CC1=CC=CC=C1.CC(N)CC1=CC=CC=C1 DAWXRFCLWKUCNS-MNTSKLTCSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 1
- CJOFXWAVKWHTFT-UHFFFAOYSA-N 2-[[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine Chemical compound COCCCCC(=NOCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-UHFFFAOYSA-N 0.000 description 1
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical compound CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 description 1
- IVHKZCSZELZKSJ-UHFFFAOYSA-N 2-hydroxyethyl sulfonate Chemical compound OCCOS(=O)=O IVHKZCSZELZKSJ-UHFFFAOYSA-N 0.000 description 1
- HMGCGUWFPZVPEK-UHFFFAOYSA-N 2-naphthalen-2-ylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=C1 HMGCGUWFPZVPEK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- GEHRSERUQRFUFW-UHFFFAOYSA-N 5-ethylhex-2-ynedioic acid Chemical compound CCC(C(O)=O)CC#CC(O)=O GEHRSERUQRFUFW-UHFFFAOYSA-N 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- JICJBGPOMZQUBB-UHFFFAOYSA-N 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid Chemical compound O=S1(=O)N(C)C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=CC=C(Cl)C=C21 JICJBGPOMZQUBB-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229940121683 Acetylcholine receptor antagonist Drugs 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 206010050012 Bradyphrenia Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010011971 Decreased interest Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- OIJXLIIMXHRJJH-KNLIIKEYSA-N Diprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)C(C)(C)O)OC)CN2CC1CC1 OIJXLIIMXHRJJH-KNLIIKEYSA-N 0.000 description 1
- 206010013496 Disturbance in attention Diseases 0.000 description 1
- 102000004073 Dopamine D3 Receptors Human genes 0.000 description 1
- 108090000525 Dopamine D3 Receptors Proteins 0.000 description 1
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000033618 Elevated mood Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 206010018671 Grandiosity Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021567 Impulsive behaviour Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
- IWVRVEIKCBFZNF-UHFFFAOYSA-N LSM-1636 Chemical compound C1CNC2CCCC3=C2N1C1=CC=C(C)C=C13 IWVRVEIKCBFZNF-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 description 1
- 229940127450 Opioid Agonists Drugs 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
- 101710184528 Scaffolding protein Proteins 0.000 description 1
- 208000033039 Somatisation disease Diseases 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042458 Suicidal ideation Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010064805 Tachyphrenia Diseases 0.000 description 1
- 206010043087 Tachyphylaxis Diseases 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229940056213 abilify Drugs 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229960002629 agomelatine Drugs 0.000 description 1
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
- 229960003036 amisulpride Drugs 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 229940030922 amphetamine aspartate monohydrate Drugs 0.000 description 1
- 229940008238 amphetamine sulfate Drugs 0.000 description 1
- PYHRZPFZZDCOPH-UHFFFAOYSA-N amphetamine sulfate Chemical compound OS(O)(=O)=O.CC(N)CC1=CC=CC=C1.CC(N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-UHFFFAOYSA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960004823 armodafinil Drugs 0.000 description 1
- YFGHCGITMMYXAQ-LJQANCHMSA-N armodafinil Chemical compound C=1C=CC=CC=1C([S@](=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-LJQANCHMSA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005245 asenapine Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 208000025748 atypical depressive disease Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 231100000871 behavioral problem Toxicity 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 229960004301 butriptyline Drugs 0.000 description 1
- ALELTFCQZDXAMQ-UHFFFAOYSA-N butriptyline Chemical compound C1CC2=CC=CC=C2C(CC(C)CN(C)C)C2=CC=CC=C21 ALELTFCQZDXAMQ-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- JOYKCMAPFCSKNO-UHFFFAOYSA-N chloro benzenesulfonate Chemical compound ClOS(=O)(=O)C1=CC=CC=C1 JOYKCMAPFCSKNO-UHFFFAOYSA-N 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 229940112502 concerta Drugs 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 108700023159 delta Opioid Receptors Proteins 0.000 description 1
- 102000048124 delta Opioid Receptors Human genes 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 229960001623 desvenlafaxine Drugs 0.000 description 1
- DUGOZIWVEXMGBE-CHWSQXEVSA-N dexmethylphenidate Chemical compound C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-CHWSQXEVSA-N 0.000 description 1
- 229960001042 dexmethylphenidate Drugs 0.000 description 1
- 229940119751 dextroamphetamine sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- BRTSNYPDACNMIP-FAWZKKEFSA-N dihydroetorphine Chemical compound O([C@H]1[C@@]2(OC)CC[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O BRTSNYPDACNMIP-FAWZKKEFSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229950002494 diprenorphine Drugs 0.000 description 1
- 239000002804 dopamine agent Substances 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 230000028436 dopamine uptake Effects 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 229960001393 dosulepin Drugs 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229940034706 duloxetine 60 mg Drugs 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- 229960005437 etoperidone Drugs 0.000 description 1
- IZBNNCFOBMGTQX-UHFFFAOYSA-N etoperidone Chemical compound O=C1N(CC)C(CC)=NN1CCCN1CCN(C=2C=C(Cl)C=CC=2)CC1 IZBNNCFOBMGTQX-UHFFFAOYSA-N 0.000 description 1
- CAHCBJPUTCKATP-FAWZKKEFSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 description 1
- 229950004155 etorphine Drugs 0.000 description 1
- 230000002743 euphoric effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000010006 flight Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 229940015509 gabapentin 300 mg Drugs 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 229960002844 iprindole Drugs 0.000 description 1
- PLIGPBGDXASWPX-UHFFFAOYSA-N iprindole Chemical compound C1CCCCCC2=C1N(CCCN(C)C)C1=CC=CC=C12 PLIGPBGDXASWPX-UHFFFAOYSA-N 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 229960002672 isocarboxazid Drugs 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229950008325 levothyroxine Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960002813 lofepramine Drugs 0.000 description 1
- SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- HTODIQZHVCHVGM-JTQLQIEISA-N lubazodone Chemical compound C1=2CCCC=2C(F)=CC=C1OC[C@@H]1CNCCO1 HTODIQZHVCHVGM-JTQLQIEISA-N 0.000 description 1
- 229950004415 lubazodone Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000003995 melancholia Diseases 0.000 description 1
- 229940068272 melatonin 3 mg Drugs 0.000 description 1
- 229940033208 melatonin 5 mg Drugs 0.000 description 1
- 229960004794 melitracen Drugs 0.000 description 1
- GWWLWDURRGNSRS-UHFFFAOYSA-N melitracen Chemical compound C1=CC=C2C(=CCCN(C)C)C3=CC=CC=C3C(C)(C)C2=C1 GWWLWDURRGNSRS-UHFFFAOYSA-N 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- 229960001165 modafinil Drugs 0.000 description 1
- 239000004050 mood stabilizer Substances 0.000 description 1
- 229940127237 mood stabilizer Drugs 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229950002220 pirlindole Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229960003770 reboxetine Drugs 0.000 description 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940023942 remeron Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229940110294 revia Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- 229940099204 ritalin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 108010085082 sigma receptors Proteins 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000016994 somatization disease Diseases 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- RKZSNTNMEFVBDT-MRVPVSSYSA-N sumanirole Chemical compound C([C@H](C1)NC)C2=CC=CC3=C2N1C(=O)N3 RKZSNTNMEFVBDT-MRVPVSSYSA-N 0.000 description 1
- 229950011111 sumanirole Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000015883 synaptic transmission, dopaminergic Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229950000505 tandospirone Drugs 0.000 description 1
- CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 229960005138 tianeptine Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- PHTUQLWOUWZIMZ-GZTJUZNOSA-N trans-dothiepin Chemical compound C1SC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 PHTUQLWOUWZIMZ-GZTJUZNOSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 239000003174 triple reuptake inhibitor Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 description 1
- 229960001255 viloxazine Drugs 0.000 description 1
- 229940057739 vivitrol Drugs 0.000 description 1
- 229940013007 vyvanse Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 229940074158 xanax Drugs 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to compositions and methods that are useful in treating various forms of depression and other disorders.
- depression refers to a serious medical illness that affects one's thoughts, feelings, behavior, mood and physical health.
- Major depression also referred to as clinical depression, major depressive illness, major affective disorder and unipolar mood disorder, may involve some combination of the following symptoms: depressed mood (sadness), poor concentration, insomnia, fatigue, appetite disturbances, excessive guilt and thoughts of suicide. Left untreated, depression can lead to serious impairment in daily functioning and even suicide. Suicide is the tenth leading cause of death in the U.S. researchers believe that more than one-half of people who die by suicide are experiencing depression. Each year depression affects 5-8 percent of adults in the United States. Therefore, about 25 million Americans will have an episode of major depression this year alone. Without treatment, the frequency and severity of depression symptoms tend to increase over time.
- ADHD attention deficit hyperactivity disorder
- Symptoms include difficulty staying focused and paying attention, difficulty controlling behavior, and hyperactivity (over-activity).
- Parkinson's disease is a degenerative disorder of the central nervous system with marked motor symptoms linked, in part, to the death of dopamine-generating cells. Common symptoms of this disorder are movement-related, including shaking, rigidity, slowness of movement and difficulty with walking and gait. Behavioral problems and dementia are also common, particularly in late stage disease.
- Bipolar disorder describes a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks.
- Obesity is a disorder marked by excessive body fat that negatively affects a patient's health. If a person's bodyweight is at least 20% higher than it should be, he or she is considered obese. Obesity is linked to a panoply of diseases, including coronary heart disease, type 2 diabetes, cancers (e.g., endometrial, breast, and colon), hypertension, dyslipidemia, stroke, liver and gallbladder disease, sleep apnea and respiratory problems, osteoarthritis, and gynecological problems, among others.
- diseases including coronary heart disease, type 2 diabetes, cancers (e.g., endometrial, breast, and colon), hypertension, dyslipidemia, stroke, liver and gallbladder disease, sleep apnea and respiratory problems, osteoarthritis, and gynecological problems, among others.
- the present invention relates to improved compositions and methods for the treatment or prevention of various forms of depression and/or mood disorders, including, for example, breakthrough depression and treatment-refractory depression, and other mood disorders as well as other ADHD, Parkinson's disease, and obesity, among others.
- the present invention provides a method of preventing or treating breakthrough depression in a patient in need thereof comprising administering an effective amount of low dose naltrexone or related opioid antagonist.
- the present invention provides a method of preventing or treating treatment-refractory depression in a patient in need thereof comprising administering an effective amount of low dose naltrexone or related opioid antagonist.
- the present invention provides a method of preventing or treating breakthrough depression in a patient in need thereof comprising administering an effective amount of low dose naltrexone or related opioid antagonist in combination with an effective amount of one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRI), and a selective serotonin re-uptake inhibitor (SSRI).
- a dopamine active anti-depressant agent e.g., a dopamine active anti-depressant agent
- SNRI serotonin-norepinephrine reuptake inhibitor
- SSRI selective serotonin re-uptake inhibitor
- the present invention provides a method of preventing or treating treatment-refractory depression in a patient in need thereof comprising administering an effective amount of low dose naltrexone or related opioid antagonist in combination with an effective amount of one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRI), and a selective serotonin re-uptake inhibitor (S SRI).
- a dopamine active anti-depressant agent e.g., a dopamine active anti-depressant agent
- SNRI serotonin-norepinephrine reuptake inhibitor
- S SRI selective serotonin re-uptake inhibitor
- the present invention provides a method of preventing or treating one or more of depression, Parkinson's disease, attention deficit disorder (ADHD). Restless Leg Syndrome (RLS), and obesity comprising administering an effective amount of low dose naltrexone or related opioid antagonist in combination with an effective amount of another agent described herein.
- ADHD attention deficit disorder
- RLS Restless Leg Syndrome
- FIGS. 1A and 1B show patient response during clinical testing of low dose naltrexone treatment for depression as measured by 17-item Hamilton Rating Scale for Depression (HAM-D-17) over three weeks ( FIG. 1A ) and six weeks ( FIG. 1B ), respectively.
- HAM-D-17 17-item Hamilton Rating Scale for Depression
- FIGS. 2A and 2B show patient response during clinical testing of low dose naltrexone treatment for depression as measured by 28-item Hamilton Rating Scale for Depression (HAM-D-28) over three weeks ( FIG. 2A ) and six weeks ( FIG. 2B ), respectively.
- HAM-D-28 28-item Hamilton Rating Scale for Depression
- FIGS. 3A and 3B show patient response during clinical testing of low dose naltrexone treatment for depression as measured by 10-item Montgomery-Asberg Depression Rating Scale (MADRS-10) over three weeks ( FIG. 3A ) and six weeks ( FIG. 3B ), respectively.
- MADRS-10 10-item Montgomery-Asberg Depression Rating Scale
- FIGS. 4A and 4B show patient response during clinical testing of low dose naltrexone treatment for depression as measured by 15-item Montgomery-Asberg Depression Rating Scale (MADRS-15) over three weeks ( FIG. 4A ) and six weeks ( FIG. 4B ), respectively.
- MADRS-15 15-item Montgomery-Asberg Depression Rating Scale
- FIGS. 5A and 5B show patient response during clinical testing of low dose naltrexone treatment for depression as measured by Clinical Global Impressions-Severity (CGI-S) over three weeks ( FIG. 5A ) and six weeks ( FIG. 5B ), respectively.
- CGI-S Clinical Global Impressions-Severity
- FIGS. 6A and 6B show patient response during clinical testing of low dose naltrexone treatment for depression as measured by Clinical Global Impressions-Improvement (CGI-I) over three weeks ( FIG. 6A ) and six weeks ( FIG. 6B ), respectively.
- CGI-I Clinical Global Impressions-Improvement
- the present invention is based, in part, on the discovery that low dose naltrexone is useful in the treatment of various forms of depression and/or mood disorders, including, for example, breakthrough depression and treatment-refractory depression, and other mood disorders.
- the present invention provides a method of preventing or treating breakthrough depression in a patient in need thereof comprising administering an effective amount of low dose naltrexone or related opioid antagonist. In one aspect, the present invention provides a use of low dose naltrexone or related opioid antagonist for the prevention or treatment of breakthrough depression.
- the present invention provides a method of preventing or treating treatment-refractory depression in a patient in need thereof comprising administering an effective amount of low dose naltrexone or related opioid antagonist.
- the present invention provides a use of low dose naltrexone or related opioid antagonist for the prevention or treatment of treatment-refractory depression.
- the present invention provides a method of preventing or treating breakthrough depression in a patient in need thereof comprising administering an effective amount of low dose naltrexone or related opioid antagonist in combination with an effective amount of one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRI), and a selective serotonin re-uptake inhibitor (SSRI).
- a dopamine active anti-depressant agent e.g., a dopamine active anti-depressant agent
- SNRI serotonin-norepinephrine reuptake inhibitor
- SSRI selective serotonin re-uptake inhibitor
- the present invention provides a use of low dose naltrexone or related opioid antagonist in combination with an effective amount of one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRI), and a selective serotonin re-uptake inhibitor (SSRI) for the prevention or treatment of breakthrough depression.
- a dopamine active anti-depressant agent e.g., a dopamine active anti-depressant agent
- SNRI serotonin-norepinephrine reuptake inhibitor
- SSRI selective serotonin re-uptake inhibitor
- the present invention provides a method of preventing or treating treatment-refractory depression in a patient in need thereof comprising administering an effective amount of low dose naltrexone or related opioid antagonist in combination with an effective amount of one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRT), and a selective serotonin re-uptake inhibitor (SSRI).
- a dopamine active anti-depressant agent e.g., a dopamine active anti-depressant agent
- SNRT serotonin-norepinephrine reuptake inhibitor
- SSRI selective serotonin re-uptake inhibitor
- the present invention provides a use of low dose naltrexone or related opioid antagonist in combination with an effective amount of one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRI), and a selective serotonin re-uptake inhibitor (SSRI) for the prevention or treatment of treatment-refractory depression.
- a dopamine active anti-depressant agent e.g., a dopamine active anti-depressant agent
- SNRI serotonin-norepinephrine reuptake inhibitor
- SSRI selective serotonin re-uptake inhibitor
- the present invention provides a method of preventing or treating one or more of depression, Parkinson's disease, bipolar disorder, bipolar mood disorder, attention deficit disorder (ADHD), Restless Leg Syndrome (RLS), and obesity comprising administering an effective amount of low dose naltrexone or related opioid antagonist optionally in combination with an effective amount of another agent described herein.
- the present invention provides a use of low dose naltrexone or related opioid antagonist optionally in combination another agent described herein for the prevention or treatment of one or more of depression, Parkinson's disease, bipolar disorder, bipolar mood disorder, attention deficit disorder (ADHD), Restless Leg Syndrome (RLS), and obesity.
- the effective amount of low dose naltrexone or related opioid antagonist or a combination of an effective amount of low dose naltrexone or related opioid antagonist in combination with an effective amount of an agent described herein is administered in conjunction with a patient's pre-existent anti-depression treatment, wherein the pre-existent anti-depression treatment comprises one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRT), and a selective serotonin re-uptake inhibitor (SSRI).
- a dopamine active anti-depressant agent comprises one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRT), and a selective serotonin re-uptake inhibitor (SSRI).
- SNRT serotonin-norepinephrine reup
- the presently described methods of treatment involve the administration of an effective amount of low dose naltrexone or related opioid antagonist in combination with an effective amount of an agent described herein. In one embodiment, the presently described methods of treatment involve the administration of an effective amount of low dose naltrexone or related opioid antagonist to a patient undergoing treatment with an effective amount of an agent described herein. In some embodiments, the effective amount of low dose naltrexone or related opioid antagonist is an adjuvant therapy to another agent described herein.
- the breakthrough depression comprises depressive relapse and/or recurrence.
- the low dose naltrexone or related opioid antagonist is administered at doses that reverse or prevent desensitization of a dopamine receptor, including, for example, the D 2 and D 3 receptors.
- the low dose naltrexone or related opioid antagonist is administered at doses that do not effect opioid receptors.
- the low dose naltrexone or related opioid antagonist is administered at doses that are substantially below levels that induce significant opioid blockade. Substantially below refers to levels are less than about 50%, or about 40%, or about 30%, or about 20%, or about 10%, or about 5%, or about 2%, or about 1% of levels that induce significant opioid blockade.
- the amount of naltrexone or related opioid antagonist administered is less than 10 mg, or about 1 to about 4 mg, or about 1 mg.
- the dopamine active anti-depressant agent is one or more of bupropion, aripiprazole, and sertraline. In some embodiments, aripiprazole is not an anti-depressant agent per se.
- the SNRT is selected from duloxetine, venlafaxine, nefazodone, and milnacipran.
- the dopamine active augmenting agent is one or more of an amphetamine salt, pramipexole, and ropinirole.
- the SSRI is selected from citalopram, dapoxetine, s-citalopram, fluoxetine, fluvoxamine, indalpine, paroxetine, and zimelidine.
- the preventing or treating of depression comprises reduction in length of a depressive episode.
- the preventing or treating of depression comprises recovery of an anti-depressive effect of the patient's pre-existent anti-depression treatment regimen.
- the preventing or treating of depression comprises a reduction in the rate of relapse after major depressive episodes.
- the preventing or treating of depression, including, breakthrough depression and/or treatment-refractory depression comprises prevention or reversal of loss of efficacy of the patient's pre-existent anti-depression treatment.
- the preventing or treating of depression comprises reduction in an effective dosage of the patient's pre-existent anti-depression treatment, which may, for example, causes one or more of a reduction in side effects and increase in patient adherence.
- the depression being treated is bipolar depression. Including, for example, treatment resistant bipolar depression.
- the effective amount of low dose naltrexone or related opioid antagonist or a combination regimen comprising naltrexone or related opioid antagonist is administered orally or subcutaneously.
- the naltrexone or related opioid antagonist and one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRT), and a selective serotonin re-uptake inhibitor (SSRI) are co-formulated in a single dosage form.
- the dosage form is an oral dosage form or a subcutaneous dosage form.
- an outcome of the methods of the present invention is rapid antidepressant response (e.g. less than about 10 days) compared to the usual latency for response to traditional antidepressant pharmacotherapy (about 3-6 weeks).
- the term “about” when used in connection with a referenced numeric indication means the referenced numeric indication plus or minus up to 10% of that referenced numeric indication.
- the language “about 50” covers the range of 45 to 55.
- an “effective amount” of a “therapeutically effective amount,” when used in connection with medical uses is an amount that is effective for providing a measurable treatment, prevention, or reduction in the rate of pathogenesis of a disease of interest.
- Effective amounts, toxicity, and therapeutic efficacy can be determined by standard pharmaceutical procedures in, for example, cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to about 50% of the population) and the ED50 (the dose therapeutically effective in about 50% of the population).
- the dosage can vary depending upon the dosage form employed and the route of administration utilized.
- the dose ratio between toxic and therapeutic effects is the therapeutic index and can be expressed as the ratio LD50/ED50.
- compositions and methods that exhibit large therapeutic indices are provided.
- a therapeutically effective dose can be estimated initially from in vitro assays, including, for example, cell culture assays.
- a dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 as determined in cell culture, or in an appropriate animal model.
- Levels of the described compositions in plasma can be measured, for example, by high performance liquid chromatography.
- the effects of any particular dosage can be monitored by a suitable bioassay. The dosage can be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment.
- the effect will result in a quantifiable change of at least about 10%, at least about 20%, at least about 30%, at least about 50%, at least about 70%, or at least about 90%. In some embodiments, the effect will result in a quantifiable change of about 10%, about 20%, about 30%, about 50%, about 70%, or even about 90% or more.
- Therapeutic benefit also includes halting or slowing the progression of the underlying disease or disorder, regardless of whether improvement is realized.
- a pharmacologically effective amount that will treat the disease recited herein will modulate the symptoms typically by at least about 10%, at least about 20%, at least about 30%, at least about 40%, or at least about 50%.
- something is “decreased” if a read-out of activity and/or effect is reduced by a significant amount, such as by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, at least about 98%, or more, up to and including at least about 100%, in the presence of an agent or stimulus relative to the absence of such modulation.
- activity is decreased and some downstream read-outs will decrease but others can increase.
- activity is “increased” if a read-out of activity and/or effect is increased by a significant amount, for example by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, at least about 98%, or more, up to and including at least about 100% or more, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 50-fold, at least about 100-fold, in the presence of an agent or stimulus, relative to the absence of such agent or stimulus.
- compositional percentages are by weight of the total composition, unless otherwise specified.
- the word “include,” and its variants is intended to be non-limiting, such that recitation of items in a list is not to the exclusion of other like items that may also be useful in the compositions and methods of this technology.
- the terms “can” and “may” and their variants are intended to be non-limiting, such that recitation that an embodiment can or may comprise certain elements or features does not exclude other embodiments of the present technology that do not contain those elements or features.
- the present invention pertains to various forms of depression and other mood disorders. Diagnosis of depressive conditions may be informed by criteria found in the American Psychiatric Association's revised fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), and the World Health Organization's International Statistical Classification of Diseases and Related Health Problems (ICD-10). Generally, depressive episode refers to a single episode and recurrent depressive disorder refers to repeated episodes. Both DSM-IV-TR and ICD-10 mark out typical depressive symptoms. ICD-10 defines three typical depressive symptoms, depressed mood, anhedonia, and reduced energy. Two of these should be present to determine depressive disorder diagnosis. DSM-IV-TR defines two main depressive symptoms, depressed mood and anhedonia. At least one of these must be present to make a diagnosis of a major depressive episode.
- Depression encompasses a large variety of disorders, including, but not limited to, the five further subtypes of major depressive disorder (MDD), i.e. melancholic depression, atypical depression, catatonic depression, postpartum depression, and seasonal affective disorder.
- MDD major depressive disorder
- the depression is dopamine-receptor related depression.
- the present depression is not related to opioid receptors.
- the present invention in some aspects, pertains to depression and mood disorders that are described and classified by the DSM codes. These can include, for example: major depressive disorder, recurrent—296.36, in full remission—296.35, in partial remission—296.31, mild—296.32, moderate—296.33, severe without psychotic features—296.34, severe with psychotic features—296.30, unspecified, as well as major depressive disorder, single episode-296.26, in full remission—296.25, in partial remission—296.21, mild—296.22, moderate-296.23, severe without psychotic features—296.24, severe with psychotic features—296.20, unspecified, as well as 311 depressive disorder, not otherwise specified (NOS). Further, codes 293.83—mood disorder due to . . . [general medical condition] and 296.90—mood disorder NOS, are included.
- the present invention includes compositions and methods for the treatment and/or prevention of the various disorders encompassed in the term depression, and related mood disorders.
- Breakthrough depression is a subset of depression that may be caused by tachyphylaxis or antidepressant tolerance, often called antidepressant “poop-out.” Breakthrough depression is often characterized as a condition in which patients experience a good initial antidepressant response which is lost over time with repeated or prolonged antidepressant treatment. This phenomenon is distinct from an initial non-response or a partial response.
- the breakthrough depression comprises depressive relapse and/or recurrence.
- Treatment-resistant depression is a subset of depression that is often characterized as a condition in which optimization of treatment or complete remission does not occur. When remission is not achieved, the probability of relapse is greater.
- the treatment-resistant depression comprises depressive relapse and/or recurrence.
- the present invention comprises treatment of other disorders individually or in combination with depression as described herein.
- the present invention includes the treatment of one or more of depression, Parkinson's disease, bipolar disorder, bipolar mood disorder, attention deficit disorder (ADHD), Restless Leg Syndrome (RLS), and obesity.
- the present invention is useful for treatment of one or more of depression, Parkinson's disease, bipolar disorder, bipolar mood disorder, ADHD, RLS, and obesity in the same subject.
- the present invention includes treatment of Parkinson's disease.
- Parkinson's disease occurs when a group of cells in the substantia nigra that produce dopamine malfunction and die.
- a subject has Parkinson's disease, his or her dopamine-producing cells begin to die, and therefore, the amount of dopamine produced in the brain decreases.
- Signals from the brain that tell the body how and when to move are therefore delivered more slowly, leaving a subject incapable of initiating and controlling movements in a normal way.
- Four symptoms of Parkinson's disease are tremor, or trembling in hands, arms, legs, jaw, and face; rigidity, or stiffness of the limbs and trunk; bradykinesia, or slowness of movement; and postural instability, or impaired balance and coordination.
- Parkinson's disease Other symptoms may include depression and other emotional changes; difficulty in swallowing, chewing, and speaking; urinary problems or constipation; skin problems; and sleep disruptions, etc. Accordingly, the methods and compositions of the present invention are useful for treatment of Parkinson's disease. In some embodiments, the present invention is useful for treatment of both Parkinson's disease and depression in the same subject.
- the present compositions and methods are useful in the treatment of Parkinson's disease and/or depression, including by way of non-limiting example, breakthrough depression and/or treatment-refractory depression, associated with and/or caused by Parkinson's disease.
- the present invention provides a method for treating Parkinson's disease and/or depression, including by way of non-limiting example, breakthrough depression and/or treatment-refractory depression, associated with and/or caused by Parkinson's disease by administering an effective amount of a low dose naltrexone to a patient in need thereof.
- the patient may also receive pre-existent and/or combination therapy that comprises one or more of the agents described herein.
- the present invention includes treatment of bipolar disorder and/or bipolar mood disorder.
- Bipolar disorder is in a class of mood disorders that is marked by dramatic changes in mood, energy and behavior.
- a key characteristic of people with bipolar disorder is alternating between episodes of mania (extreme elevated mood) and depression (extreme sadness). These episodes can last from hours to months.
- the mood disturbances are severe enough to affect the person's ability to function.
- the experience of mania can be very frightening and lead to impulsive behavior that has serious consequences for the person and the family.
- a depressive episode makes it difficult or impossible for a person to function in his or her daily life.
- Symptoms of depression include, for example, sad mood; preoccupation with failures or inadequacies; loss of self-esteem; slowed thinking, forgetfulness; difficulties in concentrating and in making decisions; loss of interest in work, hobbies, people; social isolation; lethargy or agitation; changes in appetite; oversleeping or insomnia; decreased sexual drive; and suicidal thoughts.
- Symptoms of mania include, for example, elevated, expansive mood; extreme irritability; rapid, unpredictable emotional changes; racing thoughts, flights of ideas; overreaction to stimuli; misinterpretation of events; increased interest in activities; overspending; sense of grandiosity, inflated self-esteem; excessive energy; decreased need for sleep; increased sexual drive, sexual indiscretions; and poor judgment.
- the present compositions and methods are useful in the treatment of depression, including by way of non-limiting example, breakthrough depression and/or treatment-refractory depression, associated with and/or caused by bipolar disorder and/or bipolar mood disorder.
- the present invention provides a method for treating depression, including by way of non-limiting example, breakthrough depression and/or treatment-refractory depression, associated with and/or caused by bipolar disorder and/or bipolar mood disorder by administering an effective amount of a low dose naltrexone to a patient in need thereof.
- the patient may also receive pre-existent and/or combination therapy that comprises one or more of the agents described herein.
- the pre-existent and/or combination therapy is bupropion.
- depression including by way of non-limiting example, breakthrough depression and/or treatment-refractory depression, associated with and/or caused by bipolar disorder and/or bipolar mood disorder is distinct from unipolar depression, including by way of non-limiting example, breakthrough depression and/or treatment-refractory depression.
- the present invention includes treatment of ADHD.
- ADHD is a disorder characterized by, for example, inattentiveness, over-activity, impulsivity, or a combination. Decreased phasic dopamine release is believed, without wishing to be bound by theory, to be an important deficit in ADHD. Accordingly, the methods and compositions of the present invention are useful for treatment of ADHD. In some embodiments, the present invention is useful for treatment of both ADHD and depression in the same subject.
- exemplary agents for coformulation include, but are not limited to, a methylphenidate formulation (e.g. in immediate or delayed release form, including selective enantiomers), an amphetamine formulation (e.g. in an immediate or delayed release form, including selective enantiomers), or a norepinephrine transporter inhibitor such as atomoxetine, all of whose actions are believed, without wishing to be bound by theory, to be mediated by augmentation of extracellular dopamine levels, as well as other drugs enhancing dopaminergic neurotransmission.
- Typical doses of ADDERALL, an amphetamine preparation range from a daily dose of 2.5 mg per day up to doses 30 mg given twice a day orally.
- Typical doses of CONCERTA range from 18 mg/day to 72 mg/day, generally not to exceed 2 mg/kg/day.
- Typical doses of RITALIN (methylphenidate) tablets are 10 to 60 mg/day given twice or three times per day; higher doses have been used.
- Typical doses of atomoxetine are 0.5 mg/kg to 1.4 mg/kg taken twice daily orally up to a maximum of a 100 mg daily dose. Lower doses may be effective, when co-administered or co-formulated with a low dose of naltrexone, naloxone, or other opioid receptor antagonist.
- a benefit of low dose opioid antagonists stabilizing dopamine augmentation in treatment of ADHD includes the prevention of dose escalation, therefore allowing use of lower doses of agents such as amphetamine salts and methylphenidate, which would, without wishing to be bound by theory, minimize the known cardiovascular risks of arrhythmias, hypertension and and/or tachycardia linked to an elevated lifetime probability of myocardial infarction and stroke.
- the present methods and formulations pertain to methylphenidate along with d-amphetamine.
- the present invention provides a method for treating ADHD by administering an effective amount of a low dose naltrexone to a patient in need thereof.
- the patient may also receive pre-existent and/or combination therapy that comprises one or more of the agents described herein.
- the present invention includes treatment of RLS, also known as Willis-Ekbom disease (WED).
- RLS is a disorder of the part of the nervous system that affects the legs and causes an urge to move them. Because it can interfere with sleep, it may be considered a sleep disorder.
- RLS is a neurological disorder characterized by an irresistible urge to move one's body to stop uncomfortable or odd sensations. It most commonly affects the legs, but can affect the arms, torso, head, and even phantom limbs. Moving the affected body part modulates the sensations, providing temporary relief.
- the present invention includes treatment or prevention of RLS comprising administering low dose naltrexone (or other opioid receptor antagonist), optionally in combination with any of the agents described herein.
- the present invention provides a method for treating RLS by administering an effective amount of a low dose naltrexone to a patient in need thereof.
- the patient may also receive pre-existent and/or combination therapy that comprises one or more of the agents described herein.
- the present invention includes treatment of obesity and metabolic syndrome which may accompany obesity, including, by way of non-limiting example, insulin resistance and type II diabetes.
- Bromocriptine a dopamimetic
- at a dose of 2.5 mg reduces leptin, insulin, and glucose levels in obese female human subjects and improves glycemic control in type II diabetics.
- Genetic studies have shown genetic polymorphisms of the dopamine D3 receptor which produce lesser levels of dopamine D3 signaling are more commonly seen in obese adults particularly those with binge eating disorders. Further, imaging studies have suggested that decreased dopamine D2 signaling in obese subjects and animal studies have shown that bromocriptine administered to leptin deficient animals reduces hyperphagia and adiposity.
- low dose naltrexone (or other opioid receptor antagonist), optionally in combination with any of the agents described herein, including dopamine D2 and D3 agonists and partial agonists including but not limited to bromocriptine, are useful in the treatment of obesity and metabolic syndrome which may accompany obesity.
- such treatment may enhance the metabolic effects of such dopamimetics by preventing desensitization of dopamine D2 and D3 receptors with chronic treatment.
- the present invention is useful for treatment of both obesity and metabolic syndrome which may accompany obesity and depression in the same subject.
- the present invention provides a method for treating obesity and/or metabolic syndrome which may accompany obesity, including, by way of non-limiting example, insulin resistance and type II diabetes by administering an effective amount of a low dose naltrexone to a patient in need thereof.
- the patient may also receive pre-existent and/or combination therapy that comprises one or more of the agents described herein.
- the present invention provides a method for treating binge eating disorder, including moderate to severe binge eating disorder.
- the treatment of binge eating disorder may include a combination therapy of low dose naltrexone and lisdexamfetamine (e.g. VYVANSE).
- Naltrexone (17-(cyclopropylmethyl)-4,5 ⁇ -epoxy-3,14-dihydroxymorphinan-6-one) is a small molecule agent of the following structure:
- Naltrexone is a potent, orally bioavailable opioid receptor antagonist. More specifically, without wishing to be bound by theory, naltrexone is a competitive antagonist (possibly exerting inverse agonistic effects) at mu and delta opioid receptors. It has been used clinically in the management of alcohol dependence and in the treatment of opioid dependence. In the context of alcohol dependence, naltrexone was approved by the U.S. F.D.A. in 1994. Since then a number of studies have confirmed its efficacy in reducing frequency and severity of relapse to drinking.
- the standard regimen is one 50 mg tablet per day, when administered orally or 380 mg every 4 weeks (or once a month) via intramuscular gluteal injection, alternating buttocks for an extended-release injectable suspension (e.g. VIVITROL).
- naltrexone was approved by the U.S. F.D.A. in 1984. Naltrexone may help patients overcome opioid addiction by blocking the drugs' euphoric effects.
- the standard regimen is an initial dose of 25 mg orally one time and maintenance doses of, if no withdrawal signs occur, 50 mg orally once a day, or as alternatives (e.g.
- a significant disadvantage of the prescription of an opioid antagonist, such as naltrexone and related opioid antagonists, at a usual dose is that they render a patient inaccessible to opioid analgesia in emergency situations.
- Another major limitation of the usual does of naltrexone and related opioid antagonists is that these doses of naltrexone and related opioid antagonists or inverse agonists carry a risk of hepatotoxicity.
- opioid blocking doses of naltrexone and related opioid antagonists perhaps because of their inverse agonist effect, can create dysphoria and/or possible anhedonia. This could exacerbate depression and/or promote suicidal ideation (as noted by the FDA in their warnings accompanying usual doses of naltrexone either p.o. or s.c).
- naltrexone binds to the C-terminal pentapeptide of the scaffolding protein filamin A (which is involved in receptor trafficking) with strong avidity (K D less than 5 pM), which may prevent or reverse a change in G-protein signaling in G coupled receptor systems, such as the mu opioid receptor, after prolonged stimulation by agonists (Wang, Frankfurt, & Burns, 2008 PloS One, 3(2), e1554).
- Filamin A is also found in Dopamine 2 and 3 receptors.
- compositions and methods comprising low dose naltrexone or a related opioid antagonist that reverse or prevent desensitization to D 2 /D 3 agonists. Accordingly, in some aspects of the invention there are provided compositions and methods comprising low dose naltrexone or a related opioid antagonist that do not effect opioid receptors.
- dopamine D2 and/or D2/3 agonists include, but are not limited, to pramipexole, ropinirole, bromocriptine, sumanirole, and pergolide.
- the side effects of “wearing off” and “on-off” periods, as well as loss of therapeutic efficacy of these agents, have been reported with these drugs. Without wishing to be bound by theory, these effects may be mediated by desensitization of dopamine D2 and D3 receptors.
- the present invention pertains to doses of naltrexone or related opioid antagonist that reverse or prevent desensitization of a dopamine receptor, including, for example, the D 2 and D 3 receptors.
- any dopamine receptor of the D 1 -like family and/or D 2 -like family is the dopamine receptor on which doses of naltrexone or related opioid antagonist reverse or prevent desensitization.
- the dopamine receptor is any one of the D 1 , D 2 , D 3 , D 4 , and D 5 receptors.
- the present invention pertains to doses of naltrexone or related opioid antagonist that are substantially below levels that induce significant opioid blockade.
- compositions and methods of treatment comprising other opioid antagonists related to naltrexone.
- opioid antagonists related to naltrexone.
- These compounds include, by way of non-limiting example, naloxone, diprenorphine, etorphine, dihydroetorphine, and combinations thereof.
- the amount of naltrexone or related opioid antagonist administered is less than 10 mg. In another embodiment, amount of naltrexone or related opioid antagonist administered is about 9 mg, or about 8 mg, or about 7 mg, or about 6 mg, or about 5 mg, or about 4 mg, or about 3 mg, or about 2 mg, or about 1 mg. In some embodiments, the dose of naltrexone or related opioid antagonist is less than 1 mg. In a specific embodiment, the dose of naltrexone or related opioid antagonist is 1 mg. In some embodiments, the amount of naltrexone or related opioid antagonist administered is 1 mg or greater up to and not including 5 mg.
- the amount of naltrexone or related opioid antagonist administered is 1 mg or greater, but no greater than 5 mg, or about 4 mg, or about 3 mg, or about 2 mg.
- the naltrexone or related opioid antagonist is administered orally is 1 mg or greater up to and not including 5 mg. In some embodiments, the naltrexone or related opioid antagonist is not provided for bolus administration.
- the naltrexone or related opioid antagonist is dosed monthly, or weekly, or daily, or twice daily. In a specific embodiment, the dose is twice daily (i.e. bid).
- the naltrexone or related opioid antagonist is administered at about 9, or about 8, or about 7, or about 6, or about 5, or about 4, or about 3, or about 2, or about 1 mg bid. In a specific embodiment, the dosing is 1 mg bid.
- the present invention provides for the co-administration and/or co-formulation of low dose naltrexone or related opioid antagonist and one or more additional agents. Further, in some embodiments, the invention provides administration of low dose naltrexone or related opioid antagonist in the context of pre-existent treatments (e.g. anti-depression treatments) that comprise one or more additional agents.
- pre-existent treatments e.g. anti-depression treatments
- the present invention provides the methods and compositions that comprise dopamine active anti-depressant agent.
- Dopamine active anti-depressant agents include agents that effect dopamine levels.
- the dopamine active anti-depressant agent is one or more of bupropion, aripiprazole, brexpiprazole, and sertraline.
- Bupropion (( ⁇ )-2-(tert-Butylamino)-1-(3-chlorophenyl)propan-1-one), without wishing to be bound by theory, may have its primary pharmacological action through norepinephrine-dopamine reuptake inhibition. It binds selectively to the dopamine transporter, but its behavioral effects may be attributed to its inhibition of norepinephrine reuptake. It also may act as a nicotinic acetylcholine receptor antagonist.
- Aripiprazole (7- ⁇ 4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy ⁇ -3,4-dihydroquinolin-2(1H)-one) and brexpiprazole (7- ⁇ 4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy ⁇ quinolin-2(1H)-one)), without wishing to be bound by theory, are partial dopamine agonist of the second generation class of atypical antipsychotics with additional antidepressant properties that is used in the treatment of schizophrenia, bipolar disorder, and clinical depression. It is approved by the U.S. FDA and EMA for various uses.
- Aripiprazole is a dopamimetic at low doses; for example, below 10 mg, or below 9 mg, or below 8 mg, or below 7 mg, or below 6 mg, or below 5 mg, or below 4 mg, or below 3 mg, or below 2 mg, or below 1 mg.
- the present invention comprises methods of treatment and compositions comprising low dose naltrexone or related opioid antagonist and aripiprazole.
- aripiprazole may be considered to be an anti-depressant agent.
- aripiprazole is not an anti-depressant agent.
- Sertraline ((1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine) is a compound of various mood disorder mechanisms. Without wishing to be bound by theory, it may be a dopamine active antidepressant; for example, at doses of 150 mg or above (for example, 160, or 170, or 180, or 190, or 200 mg). Without wishing to be bound by theory, it may also be an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is approved by the U.S. FDA.
- SSRI selective serotonin reuptake inhibitor
- the present invention provides methods and compositions comprising doses of sertraline at doses at which sertraline acts as an inhibitor of dopamine uptake.
- the present invention encompasses doses of sertraline of doses of above 150 mg daily or above 200 mg daily or above 250 mg daily.
- the present invention relates to a method of treating depression, including by way of non-limiting example, breakthrough depression and/or treatment-refractory depression, comprising administering a therapeutically effective low dose amount of naltrexone to a patient receiving doses of sertraline of doses of above 150 mg daily.
- the present invention relates to a method of treating depression, including by way of non-limiting example, breakthrough depression and/or treatment-refractory depression, comprising administering a therapeutically effective low dose amount of naltrexone to a patient receiving doses of sertraline of doses of above 150 mg daily as a combination therapy.
- the therapeutically effective low dose amount of naltrexone is 1 mg, optionally bid.
- the present invention provides methods and compositions that comprise serotonin-norepinephrine reuptake inhibitors (SNRIs).
- SNRIs serotonin-norepinephrine reuptake inhibitors
- SNRIs include agents which act upon, and increase, the levels of the neurotransmitters serotonin and norepinephrine, which play an important role in mood.
- the SNRT is one or more of duloxetine ((+)-(S)—N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine), venlafaxine ((RS)-1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]cyclohexanol), nefazodone (1-(3-[4-(3-chlorophenyl)piperazin-1-yl]propyl)-3-ethyl-4-(2-phenoxyethyl)-1H-1,2,4-triazol-5(4H)-one), and milnacipran ((1R*,2S*)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide).
- duloxetine ((+)-(S)—N-Methyl-3-(naphthalen-1-yl
- the present invention encompasses doses of duloxetine of doses of above 60 mg daily or above 80 mg daily or above 100 mg daily.
- the present invention relates to a method of treating depression, including by way of non-limiting example, breakthrough depression and/or treatment-refractory depression, comprising administering a therapeutically effective low dose amount of naltrexone to a patient receiving doses of duloxetine of doses of above 80 mg daily.
- the present invention relates to a method of treating depression, including by way of non-limiting example, breakthrough depression and/or treatment-refractory depression, comprising administering a therapeutically effective low dose amount of naltrexone to a patient receiving doses of duloxetine of doses of above 80 mg daily as a combination therapy.
- the therapeutically effective low dose amount of naltrexone is 1 mg bid.
- SNRIs are also provided in certain embodiments, including, for example, desvenlafaxine, tramadol, and sibutramine.
- the present invention provides the methods and compositions that comprise dopamine active augmenting agents.
- dopamine active augmenting agents include agents that may be used in the treatment of depression or other mood disorders and which have been shown to boost the antidepressant effect of a main antidepressant treatment.
- the dopamine active augmenting agent is one or more of an amphetamine salt, pramipexole, and ropinirole.
- Amphetamine salts include, for example, ADDERALL, a combination of four amphetamine salts (racemic amphetamine aspartate monohydrate, racemic amphetamine sulfate, dextroamphetamine saccharide, and dextroamphetamine sulfate).
- ADDERALL is a dopamine releasing agent, a norepinephrine releasing agent, and can be mildly serotonergic.
- Pramipexole ((S)—N 6 -propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine)
- Pramipexole (S)—N 6 -propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine)
- Ropinirole (4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one)), without wishing to be bound by theory, is also a dopamine agonist of the non-ergoline class of medications.
- the present invention provides the methods and compositions that comprise selective serotonin re-uptake inhibitors (SSRIs).
- SSRIs selective serotonin re-uptake inhibitors
- SSRIs include agents which act upon, and increase, the levels of the neurotransmitter serotonin, which plays an important role in mood.
- the SSRI is one or more of citalopram ((RS)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile), Dapoxetine (S)—N,N-dimethyl-3-(naphthalen-1-yloxy)-1-phenylpropan-1-amine), S-Citalopram ((S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile), Fluoxetine ((RS)—N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine), Fluvoxamine ((E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-2-aminoethyl
- SSRIs are also provided in certain embodiments, including, for example, citalopram, escitalopram, paroxetine, fluoxetine, and fluvoxamine.
- the invention provides further agents that may be used in the methods and compositions described herein.
- further agents may include serotonin antagonist and reuptake inhibitors (SARIs), such as, for example, etoperidone, lubazodone, nefazodone, and trazodone.
- SARIs serotonin antagonist and reuptake inhibitors
- further agents may include norepinephrine reuptake inhibitors (NRIs), such as, for example, atomoxetine, reboxetine, and viloxazine.
- NRIs norepinephrine reuptake inhibitors
- further agents may include norepinephrine-dopamine reuptake inhibitors (NDRIs), such as, for example, bupropion, dexmethylphenidate, methylphenidate, and methylphenidate.
- NDRIs norepinephrine-dopamine reuptake inhibitors
- the present invention comprises methods of treatment and compositions comprising low dose naltrexone or related opioid antagonist and methylphenidate.
- further agents may include norepinephrine-dopamine releasing agents (NDRAs), such as, for example, amphetamine, various amphetamine salts (e.g. salts of racemic amphetamine and dextroamphetamin, Adderall), dextroamphetamine, dextromethamphetamine, lysine-amphetamine (e.g. Vyvanase) and lisdexamfetamine.
- NDRAs norepinephrine-dopamine releasing agents
- amphetamine such as, for example, amphetamine, various amphetamine salts (e.g. salts of racemic amphetamine and dextroamphetamin, Adderall), dextroamphetamine, dextromethamphetamine, lysine-amphetamine (e.g. Vyvanase) and lisdexamfetamine.
- the present invention
- further agents may include tricyclic antidepressants (TCAs), such as, for example, amitriptyline, butriptyline, clomipramine, desipramine, dosulepin, doxepin, imipramine, iprindole, lofepramine, melitracen, nortriptyline, opipramol, protriptyline, and trimipramine.
- TCAs tricyclic antidepressants
- further agents may include tetracyclic antidepressants (TeCAs), such as, for example, amoxapine, maprotiline, mianseri, and mirtazapine.
- TeCAs tetracyclic antidepressants
- further agents may include monoamine oxidase inhibitors (MAOIs), such as, for example, isocarboxazid, moclobemide, phenelzine, pirlindole, selegiline, and tranylcypromine.
- MAOIs monoamine oxidase inhibitors
- further agents may include 5-HT 1A receptor partial agonists, such as, for example, buspirone, tandospirone, aripiprazole, vilazodone, and quetiapine.
- 5-HT 1A receptor partial agonists such as, for example, buspirone, tandospirone, aripiprazole, vilazodone, and quetiapine.
- further agents may include 5-HT 2 receptor partial agonists, such as, for example, aripiprazole.
- further agents may include 5-HT 2 receptor antagonists, such as, for example, agomelatine, nefazodone, quetiapine, and trimipramine.
- further agents may include 5-HT 7 receptor antagonists, such as, for example, aripiprazole and quetiapine.
- further agents may include D 2 receptor partial agonists, such as, for example, aripiprazole.
- further agents may include D 2 receptor antagonists, such as, for example, quetiapine.
- further agents may include D 3 receptor antagonists, such as, for example, aripiprazole.
- further agents may include D 4 receptor antagonists, such as, for example, aripiprazole.
- agents may include ⁇ -adrenergic receptor antagonists, such as, for example, aripiprazole, mirtazepine, and quetiapine.
- Mirtazapine (REMERON, AVANZA, ZISPIN) is a noradrenergic and specific serotonergic antidepressant (NaSSA) useful for the treatment of depression. It may be classified, without wishing to be bound by theory, as a centrally acting ⁇ 2 -adrenergic receptor antagonist.
- the present invention comprises methods of treatment and compositions comprising low dose naltrexone or related opioid antagonist and mirtazepine.
- agents may include mACh receptor antagonists, such as, for example, aripiprazole and quetiapine.
- further agents may include serotonin reuptake inhibitors (SRIs), such as, for example, aripiprazole and vilazodone.
- SRIs serotonin reuptake inhibitors
- further agents may include norepinephrine reuptake inhibitors (NRIs), such as, for example, quetiapine.
- NRIs norepinephrine reuptake inhibitors
- further agents may include selective serotonin reuptake enhancers (SSREs), such as, for example, tianeptine.
- SSREs selective serotonin reuptake enhancers
- further agents may include sigma receptor agonists, such as, for example, opipramol.
- further agents may include mood stabilizers, such as, for example, amisulpride, asenapine, carbamazepine, lamotrigine, lithium, olanzapine/fluoxetine, and valproic acid.
- mood stabilizers such as, for example, amisulpride, asenapine, carbamazepine, lamotrigine, lithium, olanzapine/fluoxetine, and valproic acid.
- the present invention provides the methods and compositions that comprise triple reuptake inhibitors, e.g., dopamine, serotonin and norepinephrine.
- triple reuptake inhibitors e.g., dopamine, serotonin and norepinephrine.
- the amount of the compounds described herein or their pharmaceutically acceptable salts are admixed with the carrier materials to produce a single dosage that can vary depending upon the subject being treated and the particular mode of administration. In vitro or in vivo assays can be employed to help identify optimal dosage ranges as well as consultation with teachings that are known in the art.
- the dosage of the compounds that can be used with naltrexone or related opioid antagonist can depend on several factors including the severity of the condition, whether the condition is to be treated or prevented, and the age, weight, and health of the subject to be treated. Additionally, pharmacogenomic (the effect of genotype on the pharmacokinetic, pharmacodynamic or efficacy profile of a therapeutic) information about a particular subject may affect dosage used.
- the exact individual dosages can be adjusted somewhat depending on a variety of factors, including the specific combination of the compounds being administered, the time of administration, the route of administration, the nature of the formulation, the rate of excretion, the particular depression and/or mood disease being treated and the severity of the disorder. Some variations in the dosage can be expected.
- the dosage of the compounds to be given with naltrexone or related opioid antagonist may be 0.001 mg/kg/day to 100 mg/kg/day, 0.01 mg/kg/day to 50 mg/kg/day, or 0.1 mg/kg/day to 10 mg/kg/day.
- the dosage of a compound of the invention and/or additional therapeutic may be 0.001 mg to 1000 mg per day, 1 mg to 600 mg per day, or 5 mg to 30 mg per day.
- the dosage of the compounds to be given with naltrexone or related opioid antagonist when administered by parenteral injection to a mammal, may be 0.1 mg to 250 mg per day, 1 mg to 20 mg per day, or 3 mg to 5 mg per day. Injections may be given up to four times daily.
- doses of low dose naltrexone or related agents are described herein.
- doses of other agents that are useful are known to those in the art (for example, those skilled in psychopharmacology).
- doses, of for example agents described herein for combination use with low dose naltrexone may be determined with reference Physicians' Desk Reference, 66th Edition, PDR Network; 2012 Edition (Dec. 27, 2011), the contents of which are incorporated by reference in its entirety.
- a suitable dosage may be in a range of about 0.1 mg/kg to about 100 mg/kg of body weight of the subject, for example, about 0.1 mg/kg, about 0.2 mg/kg, about 0.3 mg/kg, about 0.4 mg/kg, about 0.5 mg/kg, about 0.6 mg/kg, about 0.7 mg/kg, about 0.8 mg/kg, about 0.9 mg/kg, about 1 mg/kg, about 1.1 mg/kg, about 1.2 mg/kg, about 1.3 mg/kg, about 1.4 mg/kg, about 1.5 mg/kg, about 1.6 mg/kg, about 1.7 mg/kg, about 1.8 mg/kg, about 1.9 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg, about 10 mg/kg, about 11 mg/kg, about 12 mg/kg, about 13 mg/kg, about 14 mg/kg, about 15 mg/kg, about 20 mg/kg,
- the present invention provides a method of preventing or treating breakthrough depression in a patient in need thereof comprising administering an effective amount of low dose naltrexone or related opioid antagonist.
- the present invention provides a method of preventing or treating treatment-refractory depression in a patient in need thereof comprising administering an effective amount of low dose naltrexone or related opioid antagonist.
- the present invention provides a method of preventing or treating breakthrough depression in a patient in need thereof comprising administering an effective amount of low dose naltrexone or related opioid antagonist in combination with an effective amount of one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRI), and a selective serotonin re-uptake inhibitor (SSRI).
- a dopamine active anti-depressant agent e.g., a dopamine active anti-depressant agent
- SNRI serotonin-norepinephrine reuptake inhibitor
- SSRI selective serotonin re-uptake inhibitor
- the present invention provides a method of preventing or treating treatment-refractory depression in a patient in need thereof comprising administering an effective amount of low dose naltrexone or related opioid antagonist in combination with an effective amount of one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRI), and a selective serotonin re-uptake inhibitor (S SRI).
- a dopamine active anti-depressant agent e.g., a dopamine active anti-depressant agent
- SNRI serotonin-norepinephrine reuptake inhibitor
- S SRI selective serotonin re-uptake inhibitor
- the preventing or treating breakthrough depression and/or treatment-refractory depression comprises reduction in length of a depressive episode. In various embodiments, the preventing or treating breakthrough depression and/or treatment-refractory depression comprises recovery of an anti-depressive effect of the patient's pre-existent anti-depression treatment regimen. In still other various embodiments, the preventing or treating breakthrough depression and/or treatment-refractory depression comprises a reduction in the rate of relapse after major depressive episodes. In further various embodiments, the preventing or treating breakthrough depression and/or treatment-refractory depression comprises prevention or reversal of loss of efficacy of the patient's pre-existent anti-depression treatment.
- the preventing or treating breakthrough depression and/or treatment-refractory depression comprises reduction in an effective dosage of the patient's pre-existent anti-depression treatment, which may, for example, causes one or more of a reduction in side effects and an increase in patient adherence.
- the efficacy of treating depression may be assessed by various methods.
- information about grading of clinical effect can be found in Cusin, Yang, Yeung, and Fava, Rating Scales for Depression (Chapter 2) in Handbook of Clinical Rating Scales and Assessment in Psychiatry and Mental Health (Humana, 2010), Baer and Blias, eds., the contents of which are hereby incorporated by reference in their entirety.
- efficacy of treatment on depression is assessed by the Hamilton Rating Scale for Depression, for example, a 17-item or 28-item Hamilton Rating Scale for Depression (HAM-D-17 or HAM-D-28).
- efficacy may be demonstrated by a reduction in HAM-D-17 score of at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%, which signify improved response to treatment.
- efficacy may be demonstrated by a HAM-D-17 score of less than about 15, about 14, about 13, about 12, about 11, about 10, about 9, about 8, about 7.5, about 7, about 6.5, about 6, about 5.5, about 5, about 4.5, about 4, about 3.5, about 3, about 2.5, about 2, about 1.5, about 1, which signify increased remission following treatment.
- the pre-treatment patient has a HAM-D-17 score of greater than about 23, or between about 19-23, or between about 14-18, or between about 8-13. In some embodiments.
- the HAM-D-17 score effect size between patients not receiving low dose naltrexone or related opioid antagonist and patients receiving low dose naltrexone or related opioid antagonist is about 30, or about 25, or about 20, or about 15, or about 14, or about 13, or about 12, or about 11, or about 10, or about 9, or about 8, or about 7, or about 6, or about 5. In some embodiments, the HAM-D-17 score effect size between patients not receiving low dose naltrexone or related opioid antagonist and patients receiving low dose naltrexone or related opioid antagonist is between about 5 to about 15 or about 5 to about 10.
- the low dose naltrexone or related opioid antagonist causes any of the above reductions in HAM-D-17 score within about 7 days, or about 10 days, or about 14 days from initiation of treatment with low dose naltrexone or related opioid antagonist.
- any of the above reductions in HAM-D-17 score mediated by the low dose naltrexone or related opioid antagonist is durably maintained in the patient (e.g. for about, or greater than about, 3 weeks, or about, or greater than about, 1 month, or about, or greater than about, 2 months, or about, or greater than about, 3 months, or about, or greater than about, 6 months, or about, or greater than about, 1 year).
- efficacy may be demonstrated by a reduction in HAM-D-28 score of at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%, which signify improved response to treatment.
- efficacy may be demonstrated by a HAM-D-28 score of less than about 15, about 14, about 13, about 12, about 11, about 10, about 9, about 8, about 7.5, about 7, about 6.5, about 6, about 5.5, about 5, about 4.5, about 4, about 3.5, about 3, about 2.5, about 2, about 1.5, about 1, which signify increased remission following treatment.
- the pre-treatment patient has a HAM-D-28 score of greater than about 23, or between about 19-23, or between about 14-18, or between about 8-13. In some embodiments. In some embodiments, the HAM-D-28 score effect size between patients not receiving low dose naltrexone or related opioid antagonist and patients receiving low dose naltrexone or related opioid antagonist is about 30, or about 25, or about 20, or about 15, or about 14, or about 13, or about 12, or about 11, or about 10, or about 9, or about 8, or about 7, or about 6, or about 5.
- the HAM-D-28 score effect size between patients not receiving low dose naltrexone or related opioid antagonist and patients receiving low dose naltrexone or related opioid antagonist is between about 5 to about 15 or about 5 to about 10.
- the low dose naltrexone or related opioid antagonist causes any of the above reductions in HAM-D-28 score within about 7 days, or about 10 days, or about 14 days from initiation of treatment with low dose naltrexone or related opioid antagonist.
- any of the above reductions in HAM-D-28 score mediated by the low dose naltrexone or related opioid antagonist is durably maintained in the patient (e.g.
- efficacy of treatment on depression is assessed by the Montgomery-Asberg Depression Rating Scale, for example, a 10-item or 15-item Hamilton Rating Scale for Depression (MADRS-10 or MADRS-15).
- efficacy may be demonstrated by a reduction in MADRS-10 score of at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%, which signify improved response to treatment.
- efficacy may be demonstrated by a MADRS-10 score of less than about 15, about 14, about 13, about 12, about 11, about 10, about 9, about 8, about 7.5, about 7, about 6.5, about 6, about 5.5, about 5, about 4.5, about 4, about 3.5, about 3, about 2.5, about 2, about 1.5, about 1, which signify increased remission following treatment.
- the pre-treatment patient has a MADRS-10 score of greater than about 34, or between about 20-34, or between about 7-19. In some embodiments.
- the MADRS-10 score effect size between patients not receiving low dose naltrexone or related opioid antagonist and patients receiving low dose naltrexone or related opioid antagonist is about 40, or about 35, or about 30, or about 25, or about 20, or about 15, or about 14, or about 13, or about 12, or about 11, or about 10, or about 9, or about 8, or about 7, or about 6, or about 5. In some embodiments, the MADRS-10 score effect size between patients not receiving low dose naltrexone or related opioid antagonist and patients receiving low dose naltrexone or related opioid antagonist is between about 5 to about 15 or about 5 to about 10.
- the low dose naltrexone or related opioid antagonist causes any of the above reductions in MADRS-10 score within about 7 days, or about 10 days, or about 14 days from initiation of treatment with low dose naltrexone or related opioid antagonist.
- any of the above reductions in MADRS-10 score mediated by the low dose naltrexone or related opioid antagonist is durably maintained in the patient (e.g. for about, or greater than about, 3 weeks, or about, or greater than about, 1 month, or about, or greater than about, 2 months, or about, or greater than about, 3 months, or about, or greater than about, 6 months, or about, or greater than about, 1 year).
- efficacy may be demonstrated by a reduction in MADRS-15 score of at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%, which signify improved response to treatment.
- efficacy may be demonstrated by a MADRS-15 score of less than about 15, about 14, about 13, about 12, about 11, about 10, about 9, about 8, about 7.5, about 7, about 6.5, about 6, about 5.5, about 5, about 4.5, about 4, about 3.5, about 3, about 2.5, about 2, about 1.5, about 1, which signify increased remission following treatment.
- the pre-treatment patient has a MADRS-15 score of greater than about 34, or between about 20-34, or between about 7-19. In some embodiments. In some embodiments, the MADRS-15 score effect size between patients not receiving low dose naltrexone or related opioid antagonist and patients receiving low dose naltrexone or related opioid antagonist is about 40, or about 35, or about 30, or about 25, or about 20, or about 15, or about 14, or about 13, or about 12, or about 11, or about 10, or about 9, or about 8, or about 7, or about 6, or about 5.
- the MADRS-15 score effect size between patients not receiving low dose naltrexone or related opioid antagonist and patients receiving low dose naltrexone or related opioid antagonist is between about 5 to about 15 or about 5 to about 10.
- the low dose naltrexone or related opioid antagonist causes any of the above reductions in MADRS-15 score within about 7 days, or about 10 days, or about 14 days from initiation of treatment with low dose naltrexone or related opioid antagonist.
- any of the above reductions in MADRS-15 score mediated by the low dose naltrexone or related opioid antagonist is durably maintained in the patient (e.g.
- efficacy of treatment on depression is assessed by the Clinical Global Impressions-Severity and Improvement (CGI-S and CGI-I) score.
- efficacy may be demonstrated by a reduction in CGI-S score to about 4, about 3.5, about 3, about 2.5, about 2, about 1.5, about 1, or about 0.5, which signify clinical response.
- efficacy may be demonstrated by a reduction in CGI-I score to about 4, about 3.5, about 3, about 2.5, about 2, about 1.5, about 1, or about 0.5, which signify clinical response and improvement.
- the pre-treatment patient has a CGI-S or CGI-I score effect size between patients not receiving low dose naltrexone or related opioid antagonist and patients receiving low dose naltrexone or related opioid antagonist is about 1.5, or about 1.3, or about 1.0, or about 0.7, or about 0.5.
- the low dose naltrexone or related opioid antagonist causes any of the above reductions in CGI-S or CGI-I score within about 7 days, or about 10 days, or about 14 days from initiation of treatment with low dose naltrexone or related opioid antagonist.
- any of the above reductions in CGI-S or CGI-I score mediated by the low dose naltrexone or related opioid antagonist is durably maintained in the patient (e.g. for about, or greater than about, 3 weeks, or about, or greater than about, 1 month, or about, or greater than about, 2 months, or about, or greater than about, 3 months, or about, or greater than about, 6 months, or about, or greater than about, 1 year).
- the present invention relates to compositions, pharmaceutical compositions, and formulations comprising naltrexone or related opioid antagonist.
- the present invention provides pharmaceutical compositions, and formulations comprising naltrexone or related opioid antagonist and one or more additional agent.
- the additional agent is a compound described herein.
- the additional agent may be a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRT), and a selective serotonin re-uptake inhibitor (SSRI).
- the compounds described herein can possess a sufficiently basic functional group, which can react with an inorganic or organic acid, or a carboxyl group, which can react with an inorganic or organic base, to form a pharmaceutically acceptable salt.
- a pharmaceutically acceptable acid addition salt is formed from a pharmaceutically acceptable acid, as is well known in the art.
- Such salts include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2-19 (1977) and The Handbook of Pharmaceutical Salts; Properties, Selection, and Use . P. H. Stahl and C. G. Wermuth (eds.), Verlag, Zurich (Switzerland) 2002, which are hereby incorporated by reference in their entirety.
- salts include, by way of non-limiting example, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, camphorsulfonate, pamoate, phenylacetate, trifluoroacetate, acrylate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzo
- the term pharmaceutically acceptable salt also refers to a salt of the compounds of the present invention having an acidic functional group, such as a carboxylic acid functional group, and a base.
- Suitable bases include, but are not limited to, hydroxides of alkali metals such as sodium, potassium, and lithium; hydroxides of alkaline earth metal such as calcium and magnesium; hydroxides of other metals, such as aluminum and zinc; ammonia, and organic amines, such as unsubstituted or hydroxy-substituted mono-, di-, or tri-alkylamines, dicyclohexylamine; tributyl amine; pyridine; N-methyl, N-ethylamine; diethylamine; triethylamine; mono-, bis-, or tris-(2-OH-lower alkylamines), such as mono-; bis-, or tris-(2-hydroxyethyl)amine, 2-hydroxy-tert-butylamine, or tris-(hydroxymethyl)
- compositions described herein or their pharmaceutically acceptable salts which are used in accordance with the present invention may exhibit stereoisomerism by virtue of the presence of one or more asymmetric or chiral centers in the compounds.
- the present invention contemplates the various stereoisomers and mixtures thereof. Desired enantiomers can be obtained by chiral synthesis from commercially available chiral starting materials by methods well known in the art, or may be obtained from mixtures of the enantiomers by resolution using known techniques.
- the compounds described herein or their pharmaceutically acceptable salts can be administered to a subject in need thereof as a component of a composition that comprises a pharmaceutically acceptable carrier or vehicle.
- compositions can optionally comprise a suitable amount of a pharmaceutically acceptable excipient so as to provide the form for proper administration to the subject.
- Such pharmaceutical excipients can be liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
- the pharmaceutical excipients can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea and the like.
- auxiliary, stabilizing, thickening, lubricating, and coloring agents can be used.
- the pharmaceutically acceptable excipients are sterile when administered to a subject. Water is a useful excipient when the compounds of present invention or their pharmaceutically acceptable salts are administered intravenously.
- Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid excipients, specifically for injectable solutions.
- suitable pharmaceutical excipients also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
- the present compositions if desired, can also comprise minor amounts of wetting or emulsifying agents, or pH buffering agents.
- compositions and/or additional therapeutics agents can take the form of solutions, suspensions, emulsions, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form suitable for use.
- the composition is in the form of a capsule (see, e.g., U.S. Pat. No. 5,698,155).
- suitable pharmaceutical excipients are described in Remington's Pharmaceutical Sciences 1447-1676 (Alfonso R. Gennaro eds., 19th ed. 1995), incorporated herein by reference in its entirety.
- compositions for oral delivery can be in the form of tablets (by way of non-limiting example, REVIA), lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs, for example.
- Orally administered compositions can comprise one or more agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation.
- compositions can be coated to delay disintegration and absorption in the gastrointestinal tract thereby providing a sustained action over an extended period of time.
- Selectively permeable membranes surrounding an osmotically active compound of the invention are also suitable for oral administration. In these latter platforms, fluid from the environment surrounding the capsule is imbibed by the driving compound, which swells to displace the agent or agent composition through an aperture.
- These delivery platforms can provide an essentially zero order delivery profile as opposed to the spiked profiles of immediate release formulations.
- a time-delay material such as glycerol monostearate or glycerol stearate can also be useful.
- Oral compositions can include standard excipients such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, and magnesium carbonate. In one embodiment, the excipients are of pharmaceutical grade.
- compositions for intravenous administration comprise a sterile isotonic aqueous buffer. Where necessary, the compositions can also include a solubilizing agent. Compositions for intravenous administration can optionally include a local anesthetic such as lignocaine to lessen pain at the site of the injection.
- the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized-powder or water-free concentrate in a hermetically sealed container such as an ampule or sachette indicating the quantity of active agent.
- a hermetically sealed container such as an ampule or sachette indicating the quantity of active agent.
- the compounds described herein or their pharmaceutically acceptable salts are to be administered by infusion, they can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline.
- an ampule of sterile water for injection or saline can be provided so that the ingredients can be mixed prior to administration.
- Such dosage forms can be useful for providing controlled- or sustained-release of one or more active ingredients using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions.
- Suitable controlled- or sustained-release formulations known to those skilled in the art, including those described herein, can be readily selected for use with the compounds mentioned herein.
- the invention thus provides single unit dosage forms suitable for oral administration such as, but not limited to, tablets, capsules, gelcaps, and caplets that are adapted for controlled- or sustained-release.
- Controlled- or sustained-release of an active ingredient can be stimulated by various conditions, including but not limited to, changes in pH, changes in temperature, concentration or availability of enzymes, concentration or availability of water, or other physiological conditions or compounds.
- compositions can be prepared according to conventional mixing, granulating or coating methods, respectively, and the present compositions can comprise, in one embodiment, from about 0.1% to about 99%; and in another embodiment from about 1% to about 70% of the compounds described herein or their pharmaceutically acceptable salts by weight or volume.
- low dose naltexone or other compounds described herein may be administered to a subject for a period of about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, or about 12 months, or about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10 years. In some embodiments, low dose naltexone or other compounds described herein may be administered to a subject chronically.
- the compounds described herein or their pharmaceutically acceptable salts act synergistically when co-administered with another therapeutic agent and are administered at doses that are lower than the doses commonly employed when such agents are used as monotherapy.
- the dosage of compounds described herein or their pharmaceutically acceptable salts as well as the dosing schedule can depend on various parameters, including, but not limited to, the depression and/or mood disorder being treated, the subject's general health, and the administering physician's discretion.
- the compounds described herein or their pharmaceutically acceptable salts can be administered prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concurrently with, or subsequent to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of an additional therapeutic, such as, for example, one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRI), and a selective se
- an additional therapeutic such as, for example, one or more of a
- the compounds described herein or their pharmaceutically acceptable salts are administered 1 minute apart, 10 minutes apart, 30 minutes apart, less than 1 hour apart, 1 hour apart, 1 hour to 2 hours apart, 2 hours to 3 hours apart, 3 hours to 4 hours apart, 4 hours to 5 hours apart, 5 hours to 6 hours apart, 6 hours to 7 hours apart, 7 hours to 8 hours apart, 8 hours to 9 hours apart, 9 hours to 10 hours apart, 10 hours to 11 hours apart, 11 hours to 12 hours apart, no more than 24 hours apart or no more than 48 hours apart.
- Methods of administration include but are not limited to oral, subcutaneous, intradermal, intramuscular (by way of non-limiting example, intramuscular depot, such as, for instance, as described in U.S. Pat. No. 6,569,449, the contents of which are hereby incorporated by reference in its entirety), intraperitoneal, intravenous, intranasal, epidural, sublingual, intranasal, intracerebral, intravaginal, transdermal, rectally, by inhalation, or topically, particularly to the ears, nose, eyes, or skin.
- the mode of administration can be left to the discretion of the practitioner. In most instances, administration results in the release of the compounds described herein or their pharmaceutically acceptable salts into the bloodstream.
- the compounds described herein or their pharmaceutically acceptable salts can be administered orally.
- the compounds described herein or their pharmaceutically acceptable salts can also be administered by any other convenient route, for example, by intravenous infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and can be administered together with another biologically active agent. Administration can be systemic or local.
- Various delivery systems are known, e.g., encapsulation in liposomes, microparticles, microcapsules, capsules, etc., and can be used to administer the compounds described herein or their pharmaceutically acceptable salts.
- the compounds described herein or their pharmaceutically acceptable salts can be delivered in a controlled release system.
- a pump may be used (see Langer, 1990 , Science 249:1527-1533; Sefton, 1987, CRC Crit. Ref Biomed. Eng. 14:201; Buchwald et al., 1980 , Surgery 88:507; Saudek et al., 1989 , N. Engl. J. Med. 321:574).
- polymeric materials can be used (see Medical Applications of Controlled Release , Langer and Wise (eds.), CRC Pres., Boca Raton, Fla.
- Administration of the described compounds or their pharmaceutically acceptable salts can, independently, be one to four times daily or one to four times per month or one to six times per year or once every two, three, four or five years. Administration can be for the duration of one day or one month, two months, three months, six months, one year, two years, three years, and may even be for the life of the subject. Chronic, long-term administration will be indicated in many cases.
- the dosage may be administered as a single dose or divided into multiple doses.
- the dosage regimen utilizing the described compounds or their pharmaceutically acceptable salts can be selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the subject; the severity of the condition to be treated; the route of administration; the renal or hepatic function of the subject; and the specific compound of the invention employed.
- the described compounds or their pharmaceutically acceptable salts can be administered in a single daily dose, or the total daily dosage can be administered in divided doses of two, three or four times daily.
- the compounds described herein or their pharmaceutically acceptable salts and/or additional therapeutic can be assayed in vitro or in vivo for the desired therapeutic or prophylactic activity prior to use in humans. Animal model systems can be used to demonstrate safety and efficacy.
- subject is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, or baboon.
- subject and “patient” are used interchangeably.
- a subject is a human suffering from a type of depression described herein who does not also suffer from alcohol or drug dependence.
- the subject is a human. In some embodiments, the human is a pediatric human. In other embodiments, the subject is an adult human.
- the human has an age in a range of from about 0 months to about 6 months old, from about 6 to about 12 months old, from about 6 to about 18 months old, from about 18 to about 36 months old, from about 1 to about 5 years old, from about 5 to about 10 years old, from about 10 to about 15 years old, from about 15 to about 20 years old, from about 20 to about 25 years old, from about 25 to about 30 years old, from about 30 to about 35 years old, from about 35 to about 40 years old, from about 40 to about 45 years old, from about 45 to about 50 years old, from about 50 to about 55 years old, from about 55 to about 60 years old, from about 60 to about 65 years old, from about 65 to about 70 years old, from about 70 to about 75 years old, from about 75 to about 80 years old, from about 80 to about 85 years old, from about 85 to about 90 years old, from about 90 to about 95 years old or from about 95 to about 100 years old.
- the described compounds or their pharmaceutically acceptable salts can be administered prophylactically in order to prevent or slow the onset of these disorders.
- the described compounds or their pharmaceutically acceptable salts can be administered to a subject susceptible to or otherwise at risk of a particular depression and/or mood disorder and/or other disorders descried herein.
- an outcome of the methods of the present invention is rapid antidepressant response as compared to the usual latency for response to traditional antidepressant pharmacotherapy.
- a response can be less than about 1 day, or about 2 days, or about 3 days, or about 4 days, or about 5 days, or about 6 days, or about 7 days, or about 10 days, or about 2 weeks.
- the latency for response to traditional antidepressant pharmacotherapy is about 3, or about 4, or about 5, or about, 6 weeks, or about 8, or about 10 weeks.
- kits that can simplify the administration of the described compounds or their pharmaceutically acceptable salts, to a subject.
- a typical kit of the invention comprises the described compounds or their pharmaceutically acceptable salts, for example, in unit dosage form.
- the unit dosage form is a container, which can be sterile, containing an effective amount of a described compound or their pharmaceutically acceptable salts and a pharmaceutically acceptable carrier, diluent, excipient, or vehicle.
- the kit can further comprise a label or printed instructions instructing the use of described compounds or their pharmaceutically acceptable salts to treat or prevent depression and/or mood disorders and/or other disorders descried herein.
- the kit can also further comprise one or more additional therapeutic agents, for example, in unit dosage form, such as a container containing an effective amount of the other therapeutic agent.
- the kit comprises a container containing an effective amount of naltrexone or related opioid antagonist or a pharmaceutically acceptable salt thereof and an effective amount of another therapeutic agent. Examples of other therapeutic agents include, but are not limited to, those listed herein.
- Example 1 Patient Responses to Low Dose Naltrexone Treatment of Depression
- Patient #1 A middle aged female suffered severe depression with recurrent major depressive episodes. She had responded briefly to complex polypharmacy and electroconvulsive therapy, but depression usually returned within 3 weeks of these interventions.
- aripiprazole (ABILIFY)
- the patient was instructed to pulverize a tablet of naltrexone 50 mg, and take the smallest fragment with water. A sample of these fragments was later weighed, indicating she was taking on the average about 1 mg of naltrexone daily. The former pharmacologic regimen was otherwise unchanged.
- naltrexone About one week after initiating low dose naltrexone, the patient experienced marked remission. Despite minor variation in mood, she has maintained the remission for more than 6 months (continuing to present). She has remained on adjunctive naltrexone 1 mg daily.
- Patient #2 A particularly treatment-resistant patient with a depressive recurrence, was administered approximately 1 mg daily of naltrexone to a complex antidepressant regimen, which included duloxetine and riluzole. This patient demonstrated a robust response within 2 weeks, which has now been maintained for over 2 years.
- Patient #3 A female patient in her 50s presented with treatment-resistant depression. The patient was also diagnosed with Attention Deficit Disorder. The patient initially was treated with s-citalopram 15 mg, augmented by dextro-amphetamine. She responded briefly but rapidly returned to depressed mood with attention deficits. When naltrexone 1 mg was added to her treatment regime, the patient experienced a marked lifting of mood, noting that her attention was also much improved. This response was seen within days of the addition of naltrexone. She reported no adverse effects.
- Patient #4 A 62-year-old female patient weighing approximately 60 kg had suffered severe unremitting depression. She was treated with and responded to electro-convulsive therapy, but regressed within a week. Complex pharmacotherapy, including s-citalopram augmented by aripiprazole and mirtazepine, led to only transient response, with depressive symptoms returning after several days. Subsequently, the patient was prescribed 5 mg naltrexone daily with continuation of s-citalopram. The patient has remained euthymic during more than two months of observation.
- Patient #5 A female patient in her 40s had suffered severe treatment-resistant depression, exhibiting low energy, crying, unable to obtain and maintain employment, and anhedonia. She was being treated with buproprion XL 300 mg, augmented with melatonin 3 mg and N-acetyl-cysteine 1200 mg. The patient was then co-administered naltrexone 1 mg, and within two weeks, she experienced marked remission. After five months and continuing, she is no longer crying has improved motivation and interests, and has obtained meaningful employment.
- Patient #6 A male patient in his 80s with multiple major depression episodes, anhedonia, apathy, low energy and poor sleep was being treated with duloxetine 60 mg and buproprion 75 mg, and mirtazpine 15 mg. Naltrexone 1 mg was added, and within one week, the patient felt much better, stating that adding the naltrexone has a unique effect. The patient also reported that he had more energy, was sleeping better, was sexually active, and had returning interest in his hobby.
- Patient #7 A female patient in her late 50s with a brain tumor, epilepsy and somatization disorder, also demonstrated multiple depression episodes. She rarely left her couch, lived in social isolation, often cried, did not shower or get dressed. She also called and e-mailed multiple times per day. She was being treated with Effexor XR 75 mg QHS, Xanax 0.5 mg, and Clonazepam 1.5 mg. After adding naltrexone 1 mg, and gabapentin 300 mg and melatonin 5 mg, within three weeks, the patient was able to obtain employment, was socializing with friends, was less anxious. Her crying episodes were replaced with smiling and laughing.
- Patient #8 A treatment-resistant patient with depressive recurrence was being treated with pramipexole with limited benefit. The patient was then co-administered 1 mg daily of naltrexone with pramipexole. The patient demonstrated a robust response within a few weeks.
- Patient #9 A middle-age female suffered severe depression with recurrent major depressive episodes and social anxiety. She was being treated with Adderall 10 mg, levothyroxine 50 mcg, and propranol 10 mg. Naltrexone 1 mg was added to her regimen, and she experienced improvement in her depression.
- the clinical studies described herein assess the magnitude and rate of response to low dose naltrexone, as measured by change on the Hamilton Rating Scale for Depression (HAM-D-17 or HAM-D-28), compared to placebo. Additional assessments are based on the Montgomery-Asberg Depression Rating Scale (MADRS-10 or MADRS-15) and Clinical Global Impressions-Severity and Improvement (CGI-S and CGI-I).
- MADRS-10 or MADRS-15 Montgomery-Asberg Depression Rating Scale
- CGI-S and CGI-I Clinical Global Impressions-Severity and Improvement
- Inclusion criteria included an age of 18-65; written informed consent; patients meet DSM-IV criteria (by Structured Clinical Interview for DSM-IV SCID-I/P) for MDD, current; Quick Inventory of Depressive Symptomatology-Self-Rated (QIDS-SR) score of at least 12 at both screen and baseline visits; received treatment with SSRI in combination with a dopaminergic agent; or on an antidepressant with a dopaminergic mechanism of action, including SNRIs, MAOIs, TCAs, or bupropion, in adequate doses, achieved remission per ACNP Task Force guidelines (REF) for ⁇ 3 months, currently in relapse or recurrence without dose change for at least the past 4 weeks, based on meeting DSM-IV criteria for MDD.
- DSM-IV criteria by Structured Clinical Interview for DSM-IV SCID-I/P for MDD, current; Quick Inventory of Depressive Symptomatology-Self-Rated (QIDS-SR) score of at least 12 at both screen
- Dopaminergic agents here included, for example, classical stimulants from the amphetamine or methylphenidate families; the wakefulness promoting agents, modafinil and armodafinil; dopamine agonists (e.g. pramipexole); or bupropion ( ⁇ 300 mg/day to ensure significant dopamine reuptake inhibition). Additionally, low dose ( ⁇ 2.5 mg) Abilify, a D 2 partial agonist, was included as a dopamine agent. Sertraline, classified as an SSRI, had dopamine reuptake inhibiting properties believed to be relevant at higher doses ( ⁇ 150 mg) and was therefore considered a dopaminergic agent, as well as allowed as SSRI monotherapy at dopaminergic doses. SNRIs (e.g.
- TCAs e.g. nortriptyline
- both responders and non-responders who completed the double-blind phase had the option of receiving open-label adjunctive treatment with low dose naltrexone.
- Subjects who agreed to receive open-label treatment with low dose naltrexone for 3 months were seen monthly by a board-certified psychiatrist until the end of the follow-up phase.
- Subjects who completed or refused follow-up were offered a referral to a psychiatrist.
- the primary efficacy measurement was the change in 17-item Hamilton Rating Scale for Depression (HAM-D-17) score or the 28-item Hamilton Rating Scale for Depression (HAM-D-28). Secondary measures of efficacy include change in CGI-severity, with clinical or CGI-improvement (CGI-I). An additional measure of efficacy was the change in Montgomery-Asberg Depression Rating Scale (MADRS-10 or MADRS-15).
- the following instruments were administered according to the study schedule: a structured clinical interview for DSM-IV, an antidepressant treatment history questionnaire, the 17-item or 28-item Hamilton Depression Scale (HAM-D-17 or HAM-D-28), Clinical Global Impressions-severity and improvement (CGI-S, CGI-I), 10-item or 15-item Montgomery-Asberg Depression Rating Scale (MADRS-10 or MADRS-15), Quick inventory Depressive Symptomatology (Self Report) (QIDS-SR), a cognitive and physical functioning questionnaire, a sexual functioning questionnaire, the Quality of Life Satisfaction Questionnaire-short form (Q-LES-Q), and the Sheehan Disability Scale.
- HAM-D-17 or HAM-D-28 the 17-item or 28-item Hamilton Depression Scale
- CGI-S Clinical Global Impressions-severity and improvement
- MADRS-10 or MADRS-15 10-item or 15-item Montgomery-Asberg Depression Rating Scale
- QIDS-SR Quick inventory Depressive
- Low dose naltrexone showed specific efficacy for the treatment of “breakthrough depression,” an umbrella term, which encompasses depressive relapse (a depressive episode within 6 months of antidepressant response) and recurrence (a depressive episode after 6 months of response).
- Patients with breakthrough depression (BTD) on an antidepressant regimen containing a pro-dopaminergic agent assigned to treatment with low dose naltrexone (1 mg bid) demonstrated higher rates of response on all outcome measures. See figures for statistical analysis (e.g. FIGS. 1A, 2A, 3A, 4A, 5A, and 6A ).
- the response to active drug continued during the entire six week trial period (e.g. FIGS. 1B, 2B, 3B, 4B, 5B, and 6B ).
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to improved compositions and methods for the treatment or prevention of various diseases, including forms of depression, including, for example, breakthrough depression and treatment-refractory depression, and other mood disorders, as well as Parkinson's disease, bipolar disorder, bipolar disorder, attention deficit disorder (ADHD), Restless Leg Syndrome (RLS), and obesity. In some embodiments, the compositions and methods comprise low dose naltrexone or related opioid antagonists.
Description
- The present application is a continuation-in-part of U.S. patent application Ser. No. 14/410,551, which, on Dec. 22, 2014, entered the U.S. National Stage of International Patent Application No. PCT/US2014/013874, filed Jan. 30, 2014, which claims priority to U.S. Provisional Application No. 61/758,551, filed on Jan. 30, 2013 and U.S. Provisional Application No. 61/814,476, filed on Apr. 22, 2013, the contents of which are herein incorporated by reference in their entireties. The present application is related to U.S. patent application Ser. No. 12/603,235, filed Oct. 21, 2009 and U.S. patent application Ser. No. 13/758,569, filed Feb. 4, 2013, the contents of which are incorporated by reference in their entireties.
- The present invention relates to compositions and methods that are useful in treating various forms of depression and other disorders.
- Mental illnesses and obesity are increasing prevalent disorders in the modern world and require improved treatments to maximize patient quality of life and reduce health care costs.
- For instance, depression refers to a serious medical illness that affects one's thoughts, feelings, behavior, mood and physical health. Major depression, also referred to as clinical depression, major depressive illness, major affective disorder and unipolar mood disorder, may involve some combination of the following symptoms: depressed mood (sadness), poor concentration, insomnia, fatigue, appetite disturbances, excessive guilt and thoughts of suicide. Left untreated, depression can lead to serious impairment in daily functioning and even suicide. Suicide is the tenth leading cause of death in the U.S. Researchers believe that more than one-half of people who die by suicide are experiencing depression. Each year depression affects 5-8 percent of adults in the United States. Therefore, about 25 million Americans will have an episode of major depression this year alone. Without treatment, the frequency and severity of depression symptoms tend to increase over time.
- Furthermore, attention deficit hyperactivity disorder (ADHD) is one of the most common childhood disorders and can continue through adolescence and adulthood. Symptoms include difficulty staying focused and paying attention, difficulty controlling behavior, and hyperactivity (over-activity). Parkinson's disease is a degenerative disorder of the central nervous system with marked motor symptoms linked, in part, to the death of dopamine-generating cells. Common symptoms of this disorder are movement-related, including shaking, rigidity, slowness of movement and difficulty with walking and gait. Behavioral problems and dementia are also common, particularly in late stage disease. Bipolar disorder describes a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks.
- Obesity is a disorder marked by excessive body fat that negatively affects a patient's health. If a person's bodyweight is at least 20% higher than it should be, he or she is considered obese. Obesity is linked to a panoply of diseases, including coronary heart disease,
type 2 diabetes, cancers (e.g., endometrial, breast, and colon), hypertension, dyslipidemia, stroke, liver and gallbladder disease, sleep apnea and respiratory problems, osteoarthritis, and gynecological problems, among others. - Unfortunately, sufficient treatment for these disorders has proven elusive. For instance, in the context of depression, while certain pharmaceuticals have proven somewhat successful, medical practitioners face the challenge of unpredictable responses and eventual loss of effect, necessitating constant evaluation of treatments and, often, changes in treatment regimens. Further, anti-depression pharmaceuticals are often characterized by unpleasant side effects.
- Therefore, there remains a need for therapies that are useful for treating various mental illnesses and obesity.
- Accordingly, the present invention relates to improved compositions and methods for the treatment or prevention of various forms of depression and/or mood disorders, including, for example, breakthrough depression and treatment-refractory depression, and other mood disorders as well as other ADHD, Parkinson's disease, and obesity, among others.
- In one aspect, the present invention provides a method of preventing or treating breakthrough depression in a patient in need thereof comprising administering an effective amount of low dose naltrexone or related opioid antagonist.
- In another aspect, the present invention provides a method of preventing or treating treatment-refractory depression in a patient in need thereof comprising administering an effective amount of low dose naltrexone or related opioid antagonist.
- In a further aspect, the present invention provides a method of preventing or treating breakthrough depression in a patient in need thereof comprising administering an effective amount of low dose naltrexone or related opioid antagonist in combination with an effective amount of one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRI), and a selective serotonin re-uptake inhibitor (SSRI).
- In another aspect, the present invention provides a method of preventing or treating treatment-refractory depression in a patient in need thereof comprising administering an effective amount of low dose naltrexone or related opioid antagonist in combination with an effective amount of one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRI), and a selective serotonin re-uptake inhibitor (S SRI).
- In another aspect, the present invention provides a method of preventing or treating one or more of depression, Parkinson's disease, attention deficit disorder (ADHD). Restless Leg Syndrome (RLS), and obesity comprising administering an effective amount of low dose naltrexone or related opioid antagonist in combination with an effective amount of another agent described herein.
- The details of the invention are set forth in the accompanying description below. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, illustrative methods and materials are now described. Other features, objects, and advantages of the invention will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
-
FIGS. 1A and 1B show patient response during clinical testing of low dose naltrexone treatment for depression as measured by 17-item Hamilton Rating Scale for Depression (HAM-D-17) over three weeks (FIG. 1A ) and six weeks (FIG. 1B ), respectively. -
FIGS. 2A and 2B show patient response during clinical testing of low dose naltrexone treatment for depression as measured by 28-item Hamilton Rating Scale for Depression (HAM-D-28) over three weeks (FIG. 2A ) and six weeks (FIG. 2B ), respectively. -
FIGS. 3A and 3B show patient response during clinical testing of low dose naltrexone treatment for depression as measured by 10-item Montgomery-Asberg Depression Rating Scale (MADRS-10) over three weeks (FIG. 3A ) and six weeks (FIG. 3B ), respectively. -
FIGS. 4A and 4B show patient response during clinical testing of low dose naltrexone treatment for depression as measured by 15-item Montgomery-Asberg Depression Rating Scale (MADRS-15) over three weeks (FIG. 4A ) and six weeks (FIG. 4B ), respectively. -
FIGS. 5A and 5B show patient response during clinical testing of low dose naltrexone treatment for depression as measured by Clinical Global Impressions-Severity (CGI-S) over three weeks (FIG. 5A ) and six weeks (FIG. 5B ), respectively. -
FIGS. 6A and 6B show patient response during clinical testing of low dose naltrexone treatment for depression as measured by Clinical Global Impressions-Improvement (CGI-I) over three weeks (FIG. 6A ) and six weeks (FIG. 6B ), respectively. - The present invention is based, in part, on the discovery that low dose naltrexone is useful in the treatment of various forms of depression and/or mood disorders, including, for example, breakthrough depression and treatment-refractory depression, and other mood disorders.
- In one aspect, the present invention provides a method of preventing or treating breakthrough depression in a patient in need thereof comprising administering an effective amount of low dose naltrexone or related opioid antagonist. In one aspect, the present invention provides a use of low dose naltrexone or related opioid antagonist for the prevention or treatment of breakthrough depression.
- In another aspect, the present invention provides a method of preventing or treating treatment-refractory depression in a patient in need thereof comprising administering an effective amount of low dose naltrexone or related opioid antagonist. In one aspect, the present invention provides a use of low dose naltrexone or related opioid antagonist for the prevention or treatment of treatment-refractory depression.
- In a further aspect, the present invention provides a method of preventing or treating breakthrough depression in a patient in need thereof comprising administering an effective amount of low dose naltrexone or related opioid antagonist in combination with an effective amount of one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRI), and a selective serotonin re-uptake inhibitor (SSRI). In one aspect, the present invention provides a use of low dose naltrexone or related opioid antagonist in combination with an effective amount of one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRI), and a selective serotonin re-uptake inhibitor (SSRI) for the prevention or treatment of breakthrough depression.
- In another aspect, the present invention provides a method of preventing or treating treatment-refractory depression in a patient in need thereof comprising administering an effective amount of low dose naltrexone or related opioid antagonist in combination with an effective amount of one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRT), and a selective serotonin re-uptake inhibitor (SSRI). In one aspect, the present invention provides a use of low dose naltrexone or related opioid antagonist in combination with an effective amount of one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRI), and a selective serotonin re-uptake inhibitor (SSRI) for the prevention or treatment of treatment-refractory depression.
- In another aspect, the present invention provides a method of preventing or treating one or more of depression, Parkinson's disease, bipolar disorder, bipolar mood disorder, attention deficit disorder (ADHD), Restless Leg Syndrome (RLS), and obesity comprising administering an effective amount of low dose naltrexone or related opioid antagonist optionally in combination with an effective amount of another agent described herein. In another aspect, the present invention provides a use of low dose naltrexone or related opioid antagonist optionally in combination another agent described herein for the prevention or treatment of one or more of depression, Parkinson's disease, bipolar disorder, bipolar mood disorder, attention deficit disorder (ADHD), Restless Leg Syndrome (RLS), and obesity.
- In one embodiment, the effective amount of low dose naltrexone or related opioid antagonist or a combination of an effective amount of low dose naltrexone or related opioid antagonist in combination with an effective amount of an agent described herein is administered in conjunction with a patient's pre-existent anti-depression treatment, wherein the pre-existent anti-depression treatment comprises one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRT), and a selective serotonin re-uptake inhibitor (SSRI). In one embodiment, the presently described methods of treatment involve the administration of an effective amount of low dose naltrexone or related opioid antagonist in combination with an effective amount of an agent described herein. In one embodiment, the presently described methods of treatment involve the administration of an effective amount of low dose naltrexone or related opioid antagonist to a patient undergoing treatment with an effective amount of an agent described herein. In some embodiments, the effective amount of low dose naltrexone or related opioid antagonist is an adjuvant therapy to another agent described herein.
- In another embodiment, the breakthrough depression comprises depressive relapse and/or recurrence.
- In still another embodiment, the low dose naltrexone or related opioid antagonist is administered at doses that reverse or prevent desensitization of a dopamine receptor, including, for example, the D2 and D3 receptors. In still another embodiment, the low dose naltrexone or related opioid antagonist is administered at doses that do not effect opioid receptors. In still another embodiment, the low dose naltrexone or related opioid antagonist is administered at doses that are substantially below levels that induce significant opioid blockade. Substantially below refers to levels are less than about 50%, or about 40%, or about 30%, or about 20%, or about 10%, or about 5%, or about 2%, or about 1% of levels that induce significant opioid blockade. In one embodiment, the amount of naltrexone or related opioid antagonist administered is less than 10 mg, or about 1 to about 4 mg, or about 1 mg.
- In another embodiment, the dopamine active anti-depressant agent is one or more of bupropion, aripiprazole, and sertraline. In some embodiments, aripiprazole is not an anti-depressant agent per se. In another embodiment, the SNRT is selected from duloxetine, venlafaxine, nefazodone, and milnacipran. In another embodiment, the dopamine active augmenting agent is one or more of an amphetamine salt, pramipexole, and ropinirole. In another embodiment, the SSRI is selected from citalopram, dapoxetine, s-citalopram, fluoxetine, fluvoxamine, indalpine, paroxetine, and zimelidine.
- In various embodiments, the preventing or treating of depression, including, breakthrough depression and/or treatment-refractory depression, comprises reduction in length of a depressive episode. In various embodiments, the preventing or treating of depression, including, breakthrough depression and/or treatment-refractory depression, comprises recovery of an anti-depressive effect of the patient's pre-existent anti-depression treatment regimen. In still other various embodiments, the preventing or treating of depression, including, breakthrough depression and/or treatment-refractory depression, comprises a reduction in the rate of relapse after major depressive episodes. In further various embodiments, the preventing or treating of depression, including, breakthrough depression and/or treatment-refractory depression, comprises prevention or reversal of loss of efficacy of the patient's pre-existent anti-depression treatment. In various embodiments, the preventing or treating of depression, including, breakthrough depression and/or treatment-refractory depression, comprises reduction in an effective dosage of the patient's pre-existent anti-depression treatment, which may, for example, causes one or more of a reduction in side effects and increase in patient adherence. In some embodiments, the depression being treated is bipolar depression. Including, for example, treatment resistant bipolar depression.
- In another embodiment, the effective amount of low dose naltrexone or related opioid antagonist or a combination regimen comprising naltrexone or related opioid antagonist is administered orally or subcutaneously.
- In still another embodiment, the naltrexone or related opioid antagonist and one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRT), and a selective serotonin re-uptake inhibitor (SSRI) are co-formulated in a single dosage form. In various embodiments, the dosage form is an oral dosage form or a subcutaneous dosage form.
- In still another embodiment, an outcome of the methods of the present invention is rapid antidepressant response (e.g. less than about 10 days) compared to the usual latency for response to traditional antidepressant pharmacotherapy (about 3-6 weeks).
- As used herein, “a,” “an,” or “the” can mean one or more than one.
- Further, the term “about” when used in connection with a referenced numeric indication means the referenced numeric indication plus or minus up to 10% of that referenced numeric indication. For example, the language “about 50” covers the range of 45 to 55.
- An “effective amount” of a “therapeutically effective amount,” when used in connection with medical uses is an amount that is effective for providing a measurable treatment, prevention, or reduction in the rate of pathogenesis of a disease of interest.
- Effective amounts, toxicity, and therapeutic efficacy can be determined by standard pharmaceutical procedures in, for example, cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to about 50% of the population) and the ED50 (the dose therapeutically effective in about 50% of the population). The dosage can vary depending upon the dosage form employed and the route of administration utilized. The dose ratio between toxic and therapeutic effects is the therapeutic index and can be expressed as the ratio LD50/ED50. In some embodiments, compositions and methods that exhibit large therapeutic indices are provided. A therapeutically effective dose can be estimated initially from in vitro assays, including, for example, cell culture assays. Also, a dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 as determined in cell culture, or in an appropriate animal model. Levels of the described compositions in plasma can be measured, for example, by high performance liquid chromatography. The effects of any particular dosage can be monitored by a suitable bioassay. The dosage can be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment.
- In certain embodiments, the effect will result in a quantifiable change of at least about 10%, at least about 20%, at least about 30%, at least about 50%, at least about 70%, or at least about 90%. In some embodiments, the effect will result in a quantifiable change of about 10%, about 20%, about 30%, about 50%, about 70%, or even about 90% or more. Therapeutic benefit also includes halting or slowing the progression of the underlying disease or disorder, regardless of whether improvement is realized.
- In certain embodiments, a pharmacologically effective amount that will treat the disease recited herein will modulate the symptoms typically by at least about 10%, at least about 20%, at least about 30%, at least about 40%, or at least about 50%.
- As used herein, something is “decreased” if a read-out of activity and/or effect is reduced by a significant amount, such as by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, at least about 98%, or more, up to and including at least about 100%, in the presence of an agent or stimulus relative to the absence of such modulation. As will be understood by one of ordinary skill in the art, in some embodiments, activity is decreased and some downstream read-outs will decrease but others can increase.
- Conversely, activity is “increased” if a read-out of activity and/or effect is increased by a significant amount, for example by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, at least about 98%, or more, up to and including at least about 100% or more, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 50-fold, at least about 100-fold, in the presence of an agent or stimulus, relative to the absence of such agent or stimulus.
- As referred to herein, all compositional percentages are by weight of the total composition, unless otherwise specified. As used herein, the word “include,” and its variants, is intended to be non-limiting, such that recitation of items in a list is not to the exclusion of other like items that may also be useful in the compositions and methods of this technology. Similarly, the terms “can” and “may” and their variants are intended to be non-limiting, such that recitation that an embodiment can or may comprise certain elements or features does not exclude other embodiments of the present technology that do not contain those elements or features.
- Although the open-ended term “comprising,” as a synonym of terms such as including, containing, or having, is used herein to describe and claim the invention, the present invention, or embodiments thereof, may alternatively be described using alternative terms such as “consisting of” or “consisting essentially of.”
- In various aspects, the present invention pertains to various forms of depression and other mood disorders. Diagnosis of depressive conditions may be informed by criteria found in the American Psychiatric Association's revised fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), and the World Health Organization's International Statistical Classification of Diseases and Related Health Problems (ICD-10). Generally, depressive episode refers to a single episode and recurrent depressive disorder refers to repeated episodes. Both DSM-IV-TR and ICD-10 mark out typical depressive symptoms. ICD-10 defines three typical depressive symptoms, depressed mood, anhedonia, and reduced energy. Two of these should be present to determine depressive disorder diagnosis. DSM-IV-TR defines two main depressive symptoms, depressed mood and anhedonia. At least one of these must be present to make a diagnosis of a major depressive episode.
- Depression encompasses a large variety of disorders, including, but not limited to, the five further subtypes of major depressive disorder (MDD), i.e. melancholic depression, atypical depression, catatonic depression, postpartum depression, and seasonal affective disorder. In some embodiments, the depression is dopamine-receptor related depression. In some embodiments, the present depression is not related to opioid receptors.
- The present invention, in some aspects, pertains to depression and mood disorders that are described and classified by the DSM codes. These can include, for example: major depressive disorder, recurrent—296.36, in full remission—296.35, in partial remission—296.31, mild—296.32, moderate—296.33, severe without psychotic features—296.34, severe with psychotic features—296.30, unspecified, as well as major depressive disorder, single episode-296.26, in full remission—296.25, in partial remission—296.21, mild—296.22, moderate-296.23, severe without psychotic features—296.24, severe with psychotic features—296.20, unspecified, as well as 311 depressive disorder, not otherwise specified (NOS). Further, codes 293.83—mood disorder due to . . . [general medical condition] and 296.90—mood disorder NOS, are included.
- The present invention includes compositions and methods for the treatment and/or prevention of the various disorders encompassed in the term depression, and related mood disorders.
- Breakthrough depression is a subset of depression that may be caused by tachyphylaxis or antidepressant tolerance, often called antidepressant “poop-out.” Breakthrough depression is often characterized as a condition in which patients experience a good initial antidepressant response which is lost over time with repeated or prolonged antidepressant treatment. This phenomenon is distinct from an initial non-response or a partial response. In one embodiment, the breakthrough depression comprises depressive relapse and/or recurrence.
- Treatment-resistant depression is a subset of depression that is often characterized as a condition in which optimization of treatment or complete remission does not occur. When remission is not achieved, the probability of relapse is greater. In one embodiment, the treatment-resistant depression comprises depressive relapse and/or recurrence.
- Further, in some aspects, the present invention comprises treatment of other disorders individually or in combination with depression as described herein. For example, in some embodiments, the present invention includes the treatment of one or more of depression, Parkinson's disease, bipolar disorder, bipolar mood disorder, attention deficit disorder (ADHD), Restless Leg Syndrome (RLS), and obesity. In some embodiments, the present invention is useful for treatment of one or more of depression, Parkinson's disease, bipolar disorder, bipolar mood disorder, ADHD, RLS, and obesity in the same subject.
- In some embodiments, the present invention includes treatment of Parkinson's disease. Parkinson's disease occurs when a group of cells in the substantia nigra that produce dopamine malfunction and die. When a subject has Parkinson's disease, his or her dopamine-producing cells begin to die, and therefore, the amount of dopamine produced in the brain decreases. Signals from the brain that tell the body how and when to move are therefore delivered more slowly, leaving a subject incapable of initiating and controlling movements in a normal way. Four symptoms of Parkinson's disease are tremor, or trembling in hands, arms, legs, jaw, and face; rigidity, or stiffness of the limbs and trunk; bradykinesia, or slowness of movement; and postural instability, or impaired balance and coordination. Other symptoms may include depression and other emotional changes; difficulty in swallowing, chewing, and speaking; urinary problems or constipation; skin problems; and sleep disruptions, etc. Accordingly, the methods and compositions of the present invention are useful for treatment of Parkinson's disease. In some embodiments, the present invention is useful for treatment of both Parkinson's disease and depression in the same subject.
- In some embodiments, the present compositions and methods are useful in the treatment of Parkinson's disease and/or depression, including by way of non-limiting example, breakthrough depression and/or treatment-refractory depression, associated with and/or caused by Parkinson's disease. In some embodiments, the present invention provides a method for treating Parkinson's disease and/or depression, including by way of non-limiting example, breakthrough depression and/or treatment-refractory depression, associated with and/or caused by Parkinson's disease by administering an effective amount of a low dose naltrexone to a patient in need thereof. The patient may also receive pre-existent and/or combination therapy that comprises one or more of the agents described herein.
- In some embodiments, the present invention includes treatment of bipolar disorder and/or bipolar mood disorder. Bipolar disorder is in a class of mood disorders that is marked by dramatic changes in mood, energy and behavior. A key characteristic of people with bipolar disorder is alternating between episodes of mania (extreme elevated mood) and depression (extreme sadness). These episodes can last from hours to months. The mood disturbances are severe enough to affect the person's ability to function. The experience of mania can be very frightening and lead to impulsive behavior that has serious consequences for the person and the family. A depressive episode makes it difficult or impossible for a person to function in his or her daily life. Symptoms of depression include, for example, sad mood; preoccupation with failures or inadequacies; loss of self-esteem; slowed thinking, forgetfulness; difficulties in concentrating and in making decisions; loss of interest in work, hobbies, people; social isolation; lethargy or agitation; changes in appetite; oversleeping or insomnia; decreased sexual drive; and suicidal thoughts. Symptoms of mania include, for example, elevated, expansive mood; extreme irritability; rapid, unpredictable emotional changes; racing thoughts, flights of ideas; overreaction to stimuli; misinterpretation of events; increased interest in activities; overspending; sense of grandiosity, inflated self-esteem; excessive energy; decreased need for sleep; increased sexual drive, sexual indiscretions; and poor judgment.
- In some embodiments, the present compositions and methods are useful in the treatment of depression, including by way of non-limiting example, breakthrough depression and/or treatment-refractory depression, associated with and/or caused by bipolar disorder and/or bipolar mood disorder. In some embodiments, the present invention provides a method for treating depression, including by way of non-limiting example, breakthrough depression and/or treatment-refractory depression, associated with and/or caused by bipolar disorder and/or bipolar mood disorder by administering an effective amount of a low dose naltrexone to a patient in need thereof. The patient may also receive pre-existent and/or combination therapy that comprises one or more of the agents described herein. In some embodiments, the pre-existent and/or combination therapy is bupropion. In various embodiments, depression, including by way of non-limiting example, breakthrough depression and/or treatment-refractory depression, associated with and/or caused by bipolar disorder and/or bipolar mood disorder is distinct from unipolar depression, including by way of non-limiting example, breakthrough depression and/or treatment-refractory depression.
- In some embodiments, the present invention includes treatment of ADHD. ADHD is a disorder characterized by, for example, inattentiveness, over-activity, impulsivity, or a combination. Decreased phasic dopamine release is believed, without wishing to be bound by theory, to be an important deficit in ADHD. Accordingly, the methods and compositions of the present invention are useful for treatment of ADHD. In some embodiments, the present invention is useful for treatment of both ADHD and depression in the same subject.
- In the treatment of ADHD, exemplary agents for coformulation include, but are not limited to, a methylphenidate formulation (e.g. in immediate or delayed release form, including selective enantiomers), an amphetamine formulation (e.g. in an immediate or delayed release form, including selective enantiomers), or a norepinephrine transporter inhibitor such as atomoxetine, all of whose actions are believed, without wishing to be bound by theory, to be mediated by augmentation of extracellular dopamine levels, as well as other drugs enhancing dopaminergic neurotransmission. Typical doses of ADDERALL, an amphetamine preparation, range from a daily dose of 2.5 mg per day up to
doses 30 mg given twice a day orally. Typical doses of CONCERTA range from 18 mg/day to 72 mg/day, generally not to exceed 2 mg/kg/day. Typical doses of RITALIN (methylphenidate) tablets are 10 to 60 mg/day given twice or three times per day; higher doses have been used. Typical doses of atomoxetine are 0.5 mg/kg to 1.4 mg/kg taken twice daily orally up to a maximum of a 100 mg daily dose. Lower doses may be effective, when co-administered or co-formulated with a low dose of naltrexone, naloxone, or other opioid receptor antagonist. A benefit of low dose opioid antagonists stabilizing dopamine augmentation in treatment of ADHD includes the prevention of dose escalation, therefore allowing use of lower doses of agents such as amphetamine salts and methylphenidate, which would, without wishing to be bound by theory, minimize the known cardiovascular risks of arrhythmias, hypertension and and/or tachycardia linked to an elevated lifetime probability of myocardial infarction and stroke. In some embodiments, the present methods and formulations pertain to methylphenidate along with d-amphetamine. - In some embodiments, the present invention provides a method for treating ADHD by administering an effective amount of a low dose naltrexone to a patient in need thereof. The patient may also receive pre-existent and/or combination therapy that comprises one or more of the agents described herein.
- In some embodiments, the present invention includes treatment of RLS, also known as Willis-Ekbom disease (WED). RLS is a disorder of the part of the nervous system that affects the legs and causes an urge to move them. Because it can interfere with sleep, it may be considered a sleep disorder. RLS is a neurological disorder characterized by an irresistible urge to move one's body to stop uncomfortable or odd sensations. It most commonly affects the legs, but can affect the arms, torso, head, and even phantom limbs. Moving the affected body part modulates the sensations, providing temporary relief. In some embodiments, the present invention includes treatment or prevention of RLS comprising administering low dose naltrexone (or other opioid receptor antagonist), optionally in combination with any of the agents described herein.
- In some embodiments, the present invention provides a method for treating RLS by administering an effective amount of a low dose naltrexone to a patient in need thereof. The patient may also receive pre-existent and/or combination therapy that comprises one or more of the agents described herein.
- In some embodiments, the present invention includes treatment of obesity and metabolic syndrome which may accompany obesity, including, by way of non-limiting example, insulin resistance and type II diabetes. Bromocriptine, a dopamimetic, at a dose of 2.5 mg reduces leptin, insulin, and glucose levels in obese female human subjects and improves glycemic control in type II diabetics. Genetic studies have shown genetic polymorphisms of the dopamine D3 receptor which produce lesser levels of dopamine D3 signaling are more commonly seen in obese adults particularly those with binge eating disorders. Further, imaging studies have suggested that decreased dopamine D2 signaling in obese subjects and animal studies have shown that bromocriptine administered to leptin deficient animals reduces hyperphagia and adiposity. In some embodiments, low dose naltrexone (or other opioid receptor antagonist), optionally in combination with any of the agents described herein, including dopamine D2 and D3 agonists and partial agonists including but not limited to bromocriptine, are useful in the treatment of obesity and metabolic syndrome which may accompany obesity. Without wishing to be bound by theory, such treatment may enhance the metabolic effects of such dopamimetics by preventing desensitization of dopamine D2 and D3 receptors with chronic treatment. In some embodiments, the present invention is useful for treatment of both obesity and metabolic syndrome which may accompany obesity and depression in the same subject.
- In some embodiments, the present invention provides a method for treating obesity and/or metabolic syndrome which may accompany obesity, including, by way of non-limiting example, insulin resistance and type II diabetes by administering an effective amount of a low dose naltrexone to a patient in need thereof. The patient may also receive pre-existent and/or combination therapy that comprises one or more of the agents described herein. In some embodiments, the present invention provides a method for treating binge eating disorder, including moderate to severe binge eating disorder. In various embodiments, the treatment of binge eating disorder may include a combination therapy of low dose naltrexone and lisdexamfetamine (e.g. VYVANSE).
- Naltrexone (17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one) is a small molecule agent of the following structure:
- Naltrexone is a potent, orally bioavailable opioid receptor antagonist. More specifically, without wishing to be bound by theory, naltrexone is a competitive antagonist (possibly exerting inverse agonistic effects) at mu and delta opioid receptors. It has been used clinically in the management of alcohol dependence and in the treatment of opioid dependence. In the context of alcohol dependence, naltrexone was approved by the U.S. F.D.A. in 1994. Since then a number of studies have confirmed its efficacy in reducing frequency and severity of relapse to drinking. The standard regimen is one 50 mg tablet per day, when administered orally or 380 mg every 4 weeks (or once a month) via intramuscular gluteal injection, alternating buttocks for an extended-release injectable suspension (e.g. VIVITROL). In the context of opioid dependence, naltrexone was approved by the U.S. F.D.A. in 1984. Naltrexone may help patients overcome opioid addiction by blocking the drugs' euphoric effects. The standard regimen is an initial dose of 25 mg orally one time and maintenance doses of, if no withdrawal signs occur, 50 mg orally once a day, or as alternatives (e.g. to improve compliance): 50 mg orally on week days and 100 mg orally on Saturday; or 100 mg orally every other day; or 150 mg orally every third day, when administered orally or 380 mg every 4 weeks (or once a month) via intramuscular gluteal injection, alternating buttocks for an extended-release injectable suspension.
- A significant disadvantage of the prescription of an opioid antagonist, such as naltrexone and related opioid antagonists, at a usual dose is that they render a patient inaccessible to opioid analgesia in emergency situations. Another major limitation of the usual does of naltrexone and related opioid antagonists is that these doses of naltrexone and related opioid antagonists or inverse agonists carry a risk of hepatotoxicity. Further, opioid blocking doses of naltrexone and related opioid antagonists, perhaps because of their inverse agonist effect, can create dysphoria and/or possible anhedonia. This could exacerbate depression and/or promote suicidal ideation (as noted by the FDA in their warnings accompanying usual doses of naltrexone either p.o. or s.c).
- Surprisingly, low dose naltrexone (e.g. less than 10 mg) was found to enhance the effects of opioid agonists. As a possible mechanism of action, without wishing to be bound by theory, recent studies determined that naltrexone binds to the C-terminal pentapeptide of the scaffolding protein filamin A (which is involved in receptor trafficking) with strong avidity (KD less than 5 pM), which may prevent or reverse a change in G-protein signaling in G coupled receptor systems, such as the mu opioid receptor, after prolonged stimulation by agonists (Wang, Frankfurt, & Burns, 2008 PloS One, 3(2), e1554). Filamin A is also found in
Dopamine - Accordingly, in some aspects of the invention there are provided compositions and methods comprising low dose naltrexone or a related opioid antagonist that reverse or prevent desensitization to D2/D3 agonists. Accordingly, in some aspects of the invention there are provided compositions and methods comprising low dose naltrexone or a related opioid antagonist that do not effect opioid receptors. In studies regarding the illness Restless Leg Syndrome (RLS), thought to result from a deficiency of D2/D3 compared to D1 agonism, and typically treated with the D2/D3 agonists pramipexole or ropinirole, periodic limb movements of sleep were measured with Philips Respironics Actigraphy devices, confirming that low dose naltrexone allowed equivalent control of limb movements at one-half the prior dose of D2/D3 agonists (see U.S. Ser. No. 12/603,235, hereby incorporated by reference in its entirety).
- Additionally, there have been reported observations that following successful treatment of depression with SSRIs, a D2 antagonist brought return of depressive symptoms (Wilner et al., 2005, J. Affective Disorders, 86(1), 37-45, the contents of which are hereby incorporated by reference in its entirety). Analogous observations in an animal model of depression, reversed by tricyclic antidepressants, suggested that retention of sensitivity of the D2 receptor (i.e., preventing its desensitization) was essential to effective antidepressant treatments with SSRIs or SNRIs (Wilner, 2002 in Di Chiara, G. (Ed.) Handbook of Physiology: Dopamine in the CNS. Springer, Berlin, pp. 387-416, the contents of which are hereby incorporated by reference in its entirety).
- Further, in Parkinson's Disease, dopamine D2 and/or D2/3 agonists, monoamine oxidase inhibitors (MAOi), catechol-O-methyl transferase inhibitors (COMTi), and L-DOPA formulations, either separately or together have been shown to be therapeutically efficacious. The dopamine D2 and D2/3 agonists include, but are not limited, to pramipexole, ropinirole, bromocriptine, sumanirole, and pergolide. The side effects of “wearing off” and “on-off” periods, as well as loss of therapeutic efficacy of these agents, have been reported with these drugs. Without wishing to be bound by theory, these effects may be mediated by desensitization of dopamine D2 and D3 receptors.
- Accordingly, in various aspects, the present invention pertains to doses of naltrexone or related opioid antagonist that reverse or prevent desensitization of a dopamine receptor, including, for example, the D2 and D3 receptors. In other embodiments, any dopamine receptor of the D1-like family and/or D2-like family is the dopamine receptor on which doses of naltrexone or related opioid antagonist reverse or prevent desensitization. In some embodiments, the dopamine receptor is any one of the D1, D2, D3, D4, and D5 receptors. In various aspects, the present invention pertains to doses of naltrexone or related opioid antagonist that are substantially below levels that induce significant opioid blockade.
- In various aspects, the present invention also encompasses compositions and methods of treatment comprising other opioid antagonists related to naltrexone. These compounds include, by way of non-limiting example, naloxone, diprenorphine, etorphine, dihydroetorphine, and combinations thereof.
- In one embodiment, the amount of naltrexone or related opioid antagonist administered is less than 10 mg. In another embodiment, amount of naltrexone or related opioid antagonist administered is about 9 mg, or about 8 mg, or about 7 mg, or about 6 mg, or about 5 mg, or about 4 mg, or about 3 mg, or about 2 mg, or about 1 mg. In some embodiments, the dose of naltrexone or related opioid antagonist is less than 1 mg. In a specific embodiment, the dose of naltrexone or related opioid antagonist is 1 mg. In some embodiments, the amount of naltrexone or related opioid antagonist administered is 1 mg or greater up to and not including 5 mg. In some embodiments, the amount of naltrexone or related opioid antagonist administered is 1 mg or greater, but no greater than 5 mg, or about 4 mg, or about 3 mg, or about 2 mg. In an illustrative embodiment, the naltrexone or related opioid antagonist is administered orally is 1 mg or greater up to and not including 5 mg. In some embodiments, the naltrexone or related opioid antagonist is not provided for bolus administration.
- In some embodiments, the naltrexone or related opioid antagonist is dosed monthly, or weekly, or daily, or twice daily. In a specific embodiment, the dose is twice daily (i.e. bid).
- In various embodiments, the naltrexone or related opioid antagonist is administered at about 9, or about 8, or about 7, or about 6, or about 5, or about 4, or about 3, or about 2, or about 1 mg bid. In a specific embodiment, the dosing is 1 mg bid.
- In various embodiments, the present invention provides for the co-administration and/or co-formulation of low dose naltrexone or related opioid antagonist and one or more additional agents. Further, in some embodiments, the invention provides administration of low dose naltrexone or related opioid antagonist in the context of pre-existent treatments (e.g. anti-depression treatments) that comprise one or more additional agents.
- In some embodiments the present invention provides the methods and compositions that comprise dopamine active anti-depressant agent.
- Dopamine active anti-depressant agents include agents that effect dopamine levels.
- In some embodiments, the dopamine active anti-depressant agent is one or more of bupropion, aripiprazole, brexpiprazole, and sertraline.
- Bupropion ((±)-2-(tert-Butylamino)-1-(3-chlorophenyl)propan-1-one), without wishing to be bound by theory, may have its primary pharmacological action through norepinephrine-dopamine reuptake inhibition. It binds selectively to the dopamine transporter, but its behavioral effects may be attributed to its inhibition of norepinephrine reuptake. It also may act as a nicotinic acetylcholine receptor antagonist.
- Aripiprazole (7-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one) and brexpiprazole (7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1H)-one)), without wishing to be bound by theory, are partial dopamine agonist of the second generation class of atypical antipsychotics with additional antidepressant properties that is used in the treatment of schizophrenia, bipolar disorder, and clinical depression. It is approved by the U.S. FDA and EMA for various uses. Without wishing to be bound by theory, Aripiprazole is a dopamimetic at low doses; for example, below 10 mg, or below 9 mg, or below 8 mg, or below 7 mg, or below 6 mg, or below 5 mg, or below 4 mg, or below 3 mg, or below 2 mg, or below 1 mg. In some embodiments, the present invention comprises methods of treatment and compositions comprising low dose naltrexone or related opioid antagonist and aripiprazole. In some embodiments, aripiprazole may be considered to be an anti-depressant agent. In some embodiments, aripiprazole is not an anti-depressant agent.
- Sertraline ((1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine) is a compound of various mood disorder mechanisms. Without wishing to be bound by theory, it may be a dopamine active antidepressant; for example, at doses of 150 mg or above (for example, 160, or 170, or 180, or 190, or 200 mg). Without wishing to be bound by theory, it may also be an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is approved by the U.S. FDA. In some embodiments, the present invention provides methods and compositions comprising doses of sertraline at doses at which sertraline acts as an inhibitor of dopamine uptake. For example, the present invention encompasses doses of sertraline of doses of above 150 mg daily or above 200 mg daily or above 250 mg daily. In some embodiments, the present invention relates to a method of treating depression, including by way of non-limiting example, breakthrough depression and/or treatment-refractory depression, comprising administering a therapeutically effective low dose amount of naltrexone to a patient receiving doses of sertraline of doses of above 150 mg daily. In some embodiments, the present invention relates to a method of treating depression, including by way of non-limiting example, breakthrough depression and/or treatment-refractory depression, comprising administering a therapeutically effective low dose amount of naltrexone to a patient receiving doses of sertraline of doses of above 150 mg daily as a combination therapy. In some embodiments, the therapeutically effective low dose amount of naltrexone is 1 mg, optionally bid.
- In some embodiments, the present invention provides methods and compositions that comprise serotonin-norepinephrine reuptake inhibitors (SNRIs).
- SNRIs include agents which act upon, and increase, the levels of the neurotransmitters serotonin and norepinephrine, which play an important role in mood.
- In some embodiments, the SNRT is one or more of duloxetine ((+)-(S)—N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine), venlafaxine ((RS)-1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]cyclohexanol), nefazodone (1-(3-[4-(3-chlorophenyl)piperazin-1-yl]propyl)-3-ethyl-4-(2-phenoxyethyl)-1H-1,2,4-triazol-5(4H)-one), and milnacipran ((1R*,2S*)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide). These agents are approved by the U.S. FDA for various uses. For example, the present invention encompasses doses of duloxetine of doses of above 60 mg daily or above 80 mg daily or above 100 mg daily. In some embodiments, the present invention relates to a method of treating depression, including by way of non-limiting example, breakthrough depression and/or treatment-refractory depression, comprising administering a therapeutically effective low dose amount of naltrexone to a patient receiving doses of duloxetine of doses of above 80 mg daily. In some embodiments, the present invention relates to a method of treating depression, including by way of non-limiting example, breakthrough depression and/or treatment-refractory depression, comprising administering a therapeutically effective low dose amount of naltrexone to a patient receiving doses of duloxetine of doses of above 80 mg daily as a combination therapy. In some embodiments, the therapeutically effective low dose amount of naltrexone is 1 mg bid.
- Further, SNRIs are also provided in certain embodiments, including, for example, desvenlafaxine, tramadol, and sibutramine.
- In some embodiments the present invention provides the methods and compositions that comprise dopamine active augmenting agents.
- In some embodiments dopamine active augmenting agents include agents that may be used in the treatment of depression or other mood disorders and which have been shown to boost the antidepressant effect of a main antidepressant treatment.
- In some embodiments, the dopamine active augmenting agent is one or more of an amphetamine salt, pramipexole, and ropinirole.
- Amphetamine salts include, for example, ADDERALL, a combination of four amphetamine salts (racemic amphetamine aspartate monohydrate, racemic amphetamine sulfate, dextroamphetamine saccharide, and dextroamphetamine sulfate). ADDERALL, without wishing to be bound by theory, is a dopamine releasing agent, a norepinephrine releasing agent, and can be mildly serotonergic.
- Pramipexole ((S)—N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine)), without wishing to be bound by theory, is a dopamine agonist of the non-ergoline class.
- Ropinirole (4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one)), without wishing to be bound by theory, is also a dopamine agonist of the non-ergoline class of medications.
- In some embodiments, the present invention provides the methods and compositions that comprise selective serotonin re-uptake inhibitors (SSRIs).
- SSRIs include agents which act upon, and increase, the levels of the neurotransmitter serotonin, which plays an important role in mood.
- In some embodiments, the SSRI is one or more of citalopram ((RS)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile), Dapoxetine (S)—N,N-dimethyl-3-(naphthalen-1-yloxy)-1-phenylpropan-1-amine), S-Citalopram ((S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile), Fluoxetine ((RS)—N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine), Fluvoxamine ((E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-2-aminoethyl oxime), Indalpine (3-(2-piperidin-4-ylethyl)-1H-indole), Paroxetine ((3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine), and Zimelidine ((Z)-3-(4-bromophenyl)-N,N-dimethyl-3-(pyridin-3-yl)prop-2-en-1-amine).
- Further SSRIs are also provided in certain embodiments, including, for example, citalopram, escitalopram, paroxetine, fluoxetine, and fluvoxamine.
- In various other embodiments, the invention provides further agents that may be used in the methods and compositions described herein.
- For example, in some embodiments, further agents may include serotonin antagonist and reuptake inhibitors (SARIs), such as, for example, etoperidone, lubazodone, nefazodone, and trazodone.
- In other embodiments further agents may include norepinephrine reuptake inhibitors (NRIs), such as, for example, atomoxetine, reboxetine, and viloxazine.
- In still other embodiments, further agents may include norepinephrine-dopamine reuptake inhibitors (NDRIs), such as, for example, bupropion, dexmethylphenidate, methylphenidate, and methylphenidate. In some embodiments, the present invention comprises methods of treatment and compositions comprising low dose naltrexone or related opioid antagonist and methylphenidate.
- In other embodiments, further agents may include norepinephrine-dopamine releasing agents (NDRAs), such as, for example, amphetamine, various amphetamine salts (e.g. salts of racemic amphetamine and dextroamphetamin, Adderall), dextroamphetamine, dextromethamphetamine, lysine-amphetamine (e.g. Vyvanase) and lisdexamfetamine. In some embodiments, the present invention comprises methods of treatment and compositions comprising low dose naltrexone or related opioid antagonist and amphetamines.
- In yet another embodiment, further agents may include tricyclic antidepressants (TCAs), such as, for example, amitriptyline, butriptyline, clomipramine, desipramine, dosulepin, doxepin, imipramine, iprindole, lofepramine, melitracen, nortriptyline, opipramol, protriptyline, and trimipramine.
- In yet another embodiment, further agents may include tetracyclic antidepressants (TeCAs), such as, for example, amoxapine, maprotiline, mianseri, and mirtazapine.
- In other embodiments, further agents may include monoamine oxidase inhibitors (MAOIs), such as, for example, isocarboxazid, moclobemide, phenelzine, pirlindole, selegiline, and tranylcypromine.
- In other embodiments further agents may include 5-HT1A receptor partial agonists, such as, for example, buspirone, tandospirone, aripiprazole, vilazodone, and quetiapine.
- In still other embodiments further agents may include 5-HT2 receptor partial agonists, such as, for example, aripiprazole.
- In yet another embodiment, further agents may include 5-HT2 receptor antagonists, such as, for example, agomelatine, nefazodone, quetiapine, and trimipramine.
- In other embodiments further agents may include 5-HT7 receptor antagonists, such as, for example, aripiprazole and quetiapine.
- In other embodiments further agents may include D2 receptor partial agonists, such as, for example, aripiprazole.
- In still other embodiments further agents may include D2 receptor antagonists, such as, for example, quetiapine.
- In other embodiments further agents may include D3 receptor antagonists, such as, for example, aripiprazole.
- In other embodiments further agents may include D4 receptor antagonists, such as, for example, aripiprazole.
- In other embodiments agents may include α-adrenergic receptor antagonists, such as, for example, aripiprazole, mirtazepine, and quetiapine. Mirtazapine (REMERON, AVANZA, ZISPIN) is a noradrenergic and specific serotonergic antidepressant (NaSSA) useful for the treatment of depression. It may be classified, without wishing to be bound by theory, as a centrally acting α2-adrenergic receptor antagonist. In some embodiments, the present invention comprises methods of treatment and compositions comprising low dose naltrexone or related opioid antagonist and mirtazepine.
- In other embodiments agents may include mACh receptor antagonists, such as, for example, aripiprazole and quetiapine.
- In other embodiments further agents may include serotonin reuptake inhibitors (SRIs), such as, for example, aripiprazole and vilazodone.
- In other embodiments further agents may include norepinephrine reuptake inhibitors (NRIs), such as, for example, quetiapine.
- In still other embodiments further agents may include selective serotonin reuptake enhancers (SSREs), such as, for example, tianeptine.
- In other embodiments further agents may include sigma receptor agonists, such as, for example, opipramol.
- In other embodiments further agents may include mood stabilizers, such as, for example, amisulpride, asenapine, carbamazepine, lamotrigine, lithium, olanzapine/fluoxetine, and valproic acid.
- In some embodiments the present invention provides the methods and compositions that comprise triple reuptake inhibitors, e.g., dopamine, serotonin and norepinephrine.
- In some embodiments, the amount of the compounds described herein or their pharmaceutically acceptable salts are admixed with the carrier materials to produce a single dosage that can vary depending upon the subject being treated and the particular mode of administration. In vitro or in vivo assays can be employed to help identify optimal dosage ranges as well as consultation with teachings that are known in the art.
- The dosage of the compounds that can be used with naltrexone or related opioid antagonist (for example, as a co-administration and/or co-formulation or as a pre-existent anti-depression treatment) can depend on several factors including the severity of the condition, whether the condition is to be treated or prevented, and the age, weight, and health of the subject to be treated. Additionally, pharmacogenomic (the effect of genotype on the pharmacokinetic, pharmacodynamic or efficacy profile of a therapeutic) information about a particular subject may affect dosage used. Furthermore, the exact individual dosages can be adjusted somewhat depending on a variety of factors, including the specific combination of the compounds being administered, the time of administration, the route of administration, the nature of the formulation, the rate of excretion, the particular depression and/or mood disease being treated and the severity of the disorder. Some variations in the dosage can be expected.
- In some embodiments, when orally administered to a mammal, the dosage of the compounds to be given with naltrexone or related opioid antagonist (for example, as a co-administration and/or co-formulation or as a pre-existent anti-depression treatment) may be 0.001 mg/kg/day to 100 mg/kg/day, 0.01 mg/kg/day to 50 mg/kg/day, or 0.1 mg/kg/day to 10 mg/kg/day. In some embodiments, when orally administered to a human, the dosage of a compound of the invention and/or additional therapeutic may be 0.001 mg to 1000 mg per day, 1 mg to 600 mg per day, or 5 mg to 30 mg per day.
- In some embodiments, when administered by parenteral injection to a mammal, the dosage of the compounds to be given with naltrexone or related opioid antagonist (for example, as a co-administration and/or co-formulation or as a pre-existent anti-depression treatment) may be 0.1 mg to 250 mg per day, 1 mg to 20 mg per day, or 3 mg to 5 mg per day. Injections may be given up to four times daily.
- The doses of low dose naltrexone or related agents are described herein. In general, the doses of other agents that are useful are known to those in the art (for example, those skilled in psychopharmacology). For example, doses, of for example agents described herein for combination use with low dose naltrexone, may be determined with reference Physicians' Desk Reference, 66th Edition, PDR Network; 2012 Edition (Dec. 27, 2011), the contents of which are incorporated by reference in its entirety. For example, a suitable dosage may be in a range of about 0.1 mg/kg to about 100 mg/kg of body weight of the subject, for example, about 0.1 mg/kg, about 0.2 mg/kg, about 0.3 mg/kg, about 0.4 mg/kg, about 0.5 mg/kg, about 0.6 mg/kg, about 0.7 mg/kg, about 0.8 mg/kg, about 0.9 mg/kg, about 1 mg/kg, about 1.1 mg/kg, about 1.2 mg/kg, about 1.3 mg/kg, about 1.4 mg/kg, about 1.5 mg/kg, about 1.6 mg/kg, about 1.7 mg/kg, about 1.8 mg/kg, about 1.9 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg, about 10 mg/kg, about 11 mg/kg, about 12 mg/kg, about 13 mg/kg, about 14 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, or about 100 mg/kg body weight, inclusive of all values and ranges therebetween
- In one aspect, the present invention provides a method of preventing or treating breakthrough depression in a patient in need thereof comprising administering an effective amount of low dose naltrexone or related opioid antagonist.
- In another aspect, the present invention provides a method of preventing or treating treatment-refractory depression in a patient in need thereof comprising administering an effective amount of low dose naltrexone or related opioid antagonist.
- In a further aspect, the present invention provides a method of preventing or treating breakthrough depression in a patient in need thereof comprising administering an effective amount of low dose naltrexone or related opioid antagonist in combination with an effective amount of one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRI), and a selective serotonin re-uptake inhibitor (SSRI).
- In another aspect, the present invention provides a method of preventing or treating treatment-refractory depression in a patient in need thereof comprising administering an effective amount of low dose naltrexone or related opioid antagonist in combination with an effective amount of one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRI), and a selective serotonin re-uptake inhibitor (S SRI).
- In various embodiments, the preventing or treating breakthrough depression and/or treatment-refractory depression comprises reduction in length of a depressive episode. In various embodiments, the preventing or treating breakthrough depression and/or treatment-refractory depression comprises recovery of an anti-depressive effect of the patient's pre-existent anti-depression treatment regimen. In still other various embodiments, the preventing or treating breakthrough depression and/or treatment-refractory depression comprises a reduction in the rate of relapse after major depressive episodes. In further various embodiments, the preventing or treating breakthrough depression and/or treatment-refractory depression comprises prevention or reversal of loss of efficacy of the patient's pre-existent anti-depression treatment. In various embodiments, the preventing or treating breakthrough depression and/or treatment-refractory depression comprises reduction in an effective dosage of the patient's pre-existent anti-depression treatment, which may, for example, causes one or more of a reduction in side effects and an increase in patient adherence.
- The efficacy of treating depression (e.g., breakthrough depression and/or treatment-resistant or treatment-refractory depression) using methods and compositions of the present invention may be assessed by various methods. For example, information about grading of clinical effect can be found in Cusin, Yang, Yeung, and Fava, Rating Scales for Depression (Chapter 2) in Handbook of Clinical Rating Scales and Assessment in Psychiatry and Mental Health (Humana, 2010), Baer and Blias, eds., the contents of which are hereby incorporated by reference in their entirety.
- In some embodiments, efficacy of treatment on depression is assessed by the Hamilton Rating Scale for Depression, for example, a 17-item or 28-item Hamilton Rating Scale for Depression (HAM-D-17 or HAM-D-28). In an embodiment, efficacy may be demonstrated by a reduction in HAM-D-17 score of at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%, which signify improved response to treatment. Alternatively, efficacy may be demonstrated by a HAM-D-17 score of less than about 15, about 14, about 13, about 12, about 11, about 10, about 9, about 8, about 7.5, about 7, about 6.5, about 6, about 5.5, about 5, about 4.5, about 4, about 3.5, about 3, about 2.5, about 2, about 1.5, about 1, which signify increased remission following treatment. In some embodiments, the pre-treatment patient has a HAM-D-17 score of greater than about 23, or between about 19-23, or between about 14-18, or between about 8-13. In some embodiments. In some embodiments, the HAM-D-17 score effect size between patients not receiving low dose naltrexone or related opioid antagonist and patients receiving low dose naltrexone or related opioid antagonist is about 30, or about 25, or about 20, or about 15, or about 14, or about 13, or about 12, or about 11, or about 10, or about 9, or about 8, or about 7, or about 6, or about 5. In some embodiments, the HAM-D-17 score effect size between patients not receiving low dose naltrexone or related opioid antagonist and patients receiving low dose naltrexone or related opioid antagonist is between about 5 to about 15 or about 5 to about 10. In some embodiments, the low dose naltrexone or related opioid antagonist causes any of the above reductions in HAM-D-17 score within about 7 days, or about 10 days, or about 14 days from initiation of treatment with low dose naltrexone or related opioid antagonist. In some embodiments, any of the above reductions in HAM-D-17 score mediated by the low dose naltrexone or related opioid antagonist is durably maintained in the patient (e.g. for about, or greater than about, 3 weeks, or about, or greater than about, 1 month, or about, or greater than about, 2 months, or about, or greater than about, 3 months, or about, or greater than about, 6 months, or about, or greater than about, 1 year). In an embodiment, efficacy may be demonstrated by a reduction in HAM-D-28 score of at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%, which signify improved response to treatment. Alternatively, efficacy may be demonstrated by a HAM-D-28 score of less than about 15, about 14, about 13, about 12, about 11, about 10, about 9, about 8, about 7.5, about 7, about 6.5, about 6, about 5.5, about 5, about 4.5, about 4, about 3.5, about 3, about 2.5, about 2, about 1.5, about 1, which signify increased remission following treatment. In some embodiments, the pre-treatment patient has a HAM-D-28 score of greater than about 23, or between about 19-23, or between about 14-18, or between about 8-13. In some embodiments. In some embodiments, the HAM-D-28 score effect size between patients not receiving low dose naltrexone or related opioid antagonist and patients receiving low dose naltrexone or related opioid antagonist is about 30, or about 25, or about 20, or about 15, or about 14, or about 13, or about 12, or about 11, or about 10, or about 9, or about 8, or about 7, or about 6, or about 5. In some embodiments, the HAM-D-28 score effect size between patients not receiving low dose naltrexone or related opioid antagonist and patients receiving low dose naltrexone or related opioid antagonist is between about 5 to about 15 or about 5 to about 10. In some embodiments, the low dose naltrexone or related opioid antagonist causes any of the above reductions in HAM-D-28 score within about 7 days, or about 10 days, or about 14 days from initiation of treatment with low dose naltrexone or related opioid antagonist. In some embodiments, any of the above reductions in HAM-D-28 score mediated by the low dose naltrexone or related opioid antagonist is durably maintained in the patient (e.g. for about, or greater than about, 3 weeks, or about, or greater than about, 1 month, or about, or greater than about, 2 months, or about, or greater than about, 3 months, or about, or greater than about, 6 months, or about, or greater than about, 1 year).
- In some embodiments, efficacy of treatment on depression is assessed by the Montgomery-Asberg Depression Rating Scale, for example, a 10-item or 15-item Hamilton Rating Scale for Depression (MADRS-10 or MADRS-15). In an embodiment, efficacy may be demonstrated by a reduction in MADRS-10 score of at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%, which signify improved response to treatment. Alternatively, efficacy may be demonstrated by a MADRS-10 score of less than about 15, about 14, about 13, about 12, about 11, about 10, about 9, about 8, about 7.5, about 7, about 6.5, about 6, about 5.5, about 5, about 4.5, about 4, about 3.5, about 3, about 2.5, about 2, about 1.5, about 1, which signify increased remission following treatment. In some embodiments, the pre-treatment patient has a MADRS-10 score of greater than about 34, or between about 20-34, or between about 7-19. In some embodiments. In some embodiments, the MADRS-10 score effect size between patients not receiving low dose naltrexone or related opioid antagonist and patients receiving low dose naltrexone or related opioid antagonist is about 40, or about 35, or about 30, or about 25, or about 20, or about 15, or about 14, or about 13, or about 12, or about 11, or about 10, or about 9, or about 8, or about 7, or about 6, or about 5. In some embodiments, the MADRS-10 score effect size between patients not receiving low dose naltrexone or related opioid antagonist and patients receiving low dose naltrexone or related opioid antagonist is between about 5 to about 15 or about 5 to about 10. In some embodiments, the low dose naltrexone or related opioid antagonist causes any of the above reductions in MADRS-10 score within about 7 days, or about 10 days, or about 14 days from initiation of treatment with low dose naltrexone or related opioid antagonist. In some embodiments, any of the above reductions in MADRS-10 score mediated by the low dose naltrexone or related opioid antagonist is durably maintained in the patient (e.g. for about, or greater than about, 3 weeks, or about, or greater than about, 1 month, or about, or greater than about, 2 months, or about, or greater than about, 3 months, or about, or greater than about, 6 months, or about, or greater than about, 1 year).
- In an embodiment, efficacy may be demonstrated by a reduction in MADRS-15 score of at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%, which signify improved response to treatment. Alternatively, efficacy may be demonstrated by a MADRS-15 score of less than about 15, about 14, about 13, about 12, about 11, about 10, about 9, about 8, about 7.5, about 7, about 6.5, about 6, about 5.5, about 5, about 4.5, about 4, about 3.5, about 3, about 2.5, about 2, about 1.5, about 1, which signify increased remission following treatment. In some embodiments, the pre-treatment patient has a MADRS-15 score of greater than about 34, or between about 20-34, or between about 7-19. In some embodiments. In some embodiments, the MADRS-15 score effect size between patients not receiving low dose naltrexone or related opioid antagonist and patients receiving low dose naltrexone or related opioid antagonist is about 40, or about 35, or about 30, or about 25, or about 20, or about 15, or about 14, or about 13, or about 12, or about 11, or about 10, or about 9, or about 8, or about 7, or about 6, or about 5. In some embodiments, the MADRS-15 score effect size between patients not receiving low dose naltrexone or related opioid antagonist and patients receiving low dose naltrexone or related opioid antagonist is between about 5 to about 15 or about 5 to about 10. In some embodiments, the low dose naltrexone or related opioid antagonist causes any of the above reductions in MADRS-15 score within about 7 days, or about 10 days, or about 14 days from initiation of treatment with low dose naltrexone or related opioid antagonist. In some embodiments, any of the above reductions in MADRS-15 score mediated by the low dose naltrexone or related opioid antagonist is durably maintained in the patient (e.g. for about, or greater than about, 3 weeks, or about, or greater than about, 1 month, or about, or greater than about, 2 months, or about, or greater than about, 3 months, or about, or greater than about, 6 months, or about, or greater than about, 1 year).
- In some embodiments, efficacy of treatment on depression is assessed by the Clinical Global Impressions-Severity and Improvement (CGI-S and CGI-I) score. In an embodiment, efficacy may be demonstrated by a reduction in CGI-S score to about 4, about 3.5, about 3, about 2.5, about 2, about 1.5, about 1, or about 0.5, which signify clinical response. In an embodiment, efficacy may be demonstrated by a reduction in CGI-I score to about 4, about 3.5, about 3, about 2.5, about 2, about 1.5, about 1, or about 0.5, which signify clinical response and improvement. In some embodiments, the pre-treatment patient has a CGI-S or CGI-I score effect size between patients not receiving low dose naltrexone or related opioid antagonist and patients receiving low dose naltrexone or related opioid antagonist is about 1.5, or about 1.3, or about 1.0, or about 0.7, or about 0.5. In some embodiments, the low dose naltrexone or related opioid antagonist causes any of the above reductions in CGI-S or CGI-I score within about 7 days, or about 10 days, or about 14 days from initiation of treatment with low dose naltrexone or related opioid antagonist. In some embodiments, any of the above reductions in CGI-S or CGI-I score mediated by the low dose naltrexone or related opioid antagonist is durably maintained in the patient (e.g. for about, or greater than about, 3 weeks, or about, or greater than about, 1 month, or about, or greater than about, 2 months, or about, or greater than about, 3 months, or about, or greater than about, 6 months, or about, or greater than about, 1 year).
- In various aspects, the present invention relates to compositions, pharmaceutical compositions, and formulations comprising naltrexone or related opioid antagonist. In various embodiments, the present invention provides pharmaceutical compositions, and formulations comprising naltrexone or related opioid antagonist and one or more additional agent. In some embodiments, the additional agent is a compound described herein. By way of non-limiting example, the additional agent may be a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRT), and a selective serotonin re-uptake inhibitor (SSRI).
- The compounds described herein can possess a sufficiently basic functional group, which can react with an inorganic or organic acid, or a carboxyl group, which can react with an inorganic or organic base, to form a pharmaceutically acceptable salt. A pharmaceutically acceptable acid addition salt is formed from a pharmaceutically acceptable acid, as is well known in the art. Such salts include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2-19 (1977) and The Handbook of Pharmaceutical Salts; Properties, Selection, and Use. P. H. Stahl and C. G. Wermuth (eds.), Verlag, Zurich (Switzerland) 2002, which are hereby incorporated by reference in their entirety.
- Pharmaceutically acceptable salts include, by way of non-limiting example, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, camphorsulfonate, pamoate, phenylacetate, trifluoroacetate, acrylate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, isobutyrate, phenylbutyrate, α-hydroxybutyrate, butyne-1,4-dicarboxylate, hexyne-1,4-dicarboxylate, caprate, caprylate, cinnamate, glycollate, heptanoate, hippurate, malate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, phthalate, teraphthalate, propiolate, propionate, phenylpropionate, sebacate, suberate, p-bromobenzenesulfonate, chlorobenzenesulfonate, ethylsulfonate, 2-hydroxyethylsulfonate, methylsulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, naphthalene-1,5-sulfonate, xylenesulfonate, and tartarate salts.
- The term pharmaceutically acceptable salt also refers to a salt of the compounds of the present invention having an acidic functional group, such as a carboxylic acid functional group, and a base. Suitable bases include, but are not limited to, hydroxides of alkali metals such as sodium, potassium, and lithium; hydroxides of alkaline earth metal such as calcium and magnesium; hydroxides of other metals, such as aluminum and zinc; ammonia, and organic amines, such as unsubstituted or hydroxy-substituted mono-, di-, or tri-alkylamines, dicyclohexylamine; tributyl amine; pyridine; N-methyl, N-ethylamine; diethylamine; triethylamine; mono-, bis-, or tris-(2-OH-lower alkylamines), such as mono-; bis-, or tris-(2-hydroxyethyl)amine, 2-hydroxy-tert-butylamine, or tris-(hydroxymethyl)methylamine, N,N-di-lower alkyl-N-(hydroxyl-lower alkyl)-amines, such as N,N-dimethyl-N-(2-hydroxyethyl)amine or tri-(2-hydroxyethyl)amine; N-methyl-D-glucamine; and amino acids such as arginine, lysine, and the like.
- The compositions described herein or their pharmaceutically acceptable salts which are used in accordance with the present invention may exhibit stereoisomerism by virtue of the presence of one or more asymmetric or chiral centers in the compounds. The present invention contemplates the various stereoisomers and mixtures thereof. Desired enantiomers can be obtained by chiral synthesis from commercially available chiral starting materials by methods well known in the art, or may be obtained from mixtures of the enantiomers by resolution using known techniques.
- The compounds described herein or their pharmaceutically acceptable salts can be administered to a subject in need thereof as a component of a composition that comprises a pharmaceutically acceptable carrier or vehicle.
- The present compositions can optionally comprise a suitable amount of a pharmaceutically acceptable excipient so as to provide the form for proper administration to the subject.
- Such pharmaceutical excipients can be liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The pharmaceutical excipients can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea and the like. In addition, auxiliary, stabilizing, thickening, lubricating, and coloring agents can be used. In one embodiment, the pharmaceutically acceptable excipients are sterile when administered to a subject. Water is a useful excipient when the compounds of present invention or their pharmaceutically acceptable salts are administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid excipients, specifically for injectable solutions. Suitable pharmaceutical excipients also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The present compositions, if desired, can also comprise minor amounts of wetting or emulsifying agents, or pH buffering agents.
- The present compositions and/or additional therapeutics agents can take the form of solutions, suspensions, emulsions, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form suitable for use. In one embodiment, the composition is in the form of a capsule (see, e.g., U.S. Pat. No. 5,698,155). Other examples of suitable pharmaceutical excipients are described in Remington's Pharmaceutical Sciences 1447-1676 (Alfonso R. Gennaro eds., 19th ed. 1995), incorporated herein by reference in its entirety.
- In one embodiment, the compounds described herein are formulated in accordance with routine procedures as a composition adapted for oral administration to human beings. Compositions for oral delivery can be in the form of tablets (by way of non-limiting example, REVIA), lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs, for example. Orally administered compositions can comprise one or more agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation. Moreover, where in tablet or pill form, the compositions can be coated to delay disintegration and absorption in the gastrointestinal tract thereby providing a sustained action over an extended period of time. Selectively permeable membranes surrounding an osmotically active compound of the invention are also suitable for oral administration. In these latter platforms, fluid from the environment surrounding the capsule is imbibed by the driving compound, which swells to displace the agent or agent composition through an aperture. These delivery platforms can provide an essentially zero order delivery profile as opposed to the spiked profiles of immediate release formulations. A time-delay material such as glycerol monostearate or glycerol stearate can also be useful. Oral compositions can include standard excipients such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, and magnesium carbonate. In one embodiment, the excipients are of pharmaceutical grade.
- In another embodiment, the compounds described herein or their pharmaceutically acceptable salts can be formulated for intravenous administration. Typically, compositions for intravenous administration comprise a sterile isotonic aqueous buffer. Where necessary, the compositions can also include a solubilizing agent. Compositions for intravenous administration can optionally include a local anesthetic such as lignocaine to lessen pain at the site of the injection.
- Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized-powder or water-free concentrate in a hermetically sealed container such as an ampule or sachette indicating the quantity of active agent. Where the compounds described herein or their pharmaceutically acceptable salts are to be administered by infusion, they can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the compounds described herein or their pharmaceutically acceptable salts are administered by injection, an ampule of sterile water for injection or saline can be provided so that the ingredients can be mixed prior to administration.
- Where the compounds described herein or their pharmaceutically acceptable salts can be administered by controlled-release or sustained-release means or by delivery devices that are well known to those of ordinary skill in the art. Examples include, but are not limited to, those described in U.S. Pat. Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354,556; and 5,733,556, each of which is incorporated herein by reference in its entirety. Such dosage forms can be useful for providing controlled- or sustained-release of one or more active ingredients using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions. Suitable controlled- or sustained-release formulations known to those skilled in the art, including those described herein, can be readily selected for use with the compounds mentioned herein. The invention thus provides single unit dosage forms suitable for oral administration such as, but not limited to, tablets, capsules, gelcaps, and caplets that are adapted for controlled- or sustained-release.
- Controlled- or sustained-release of an active ingredient can be stimulated by various conditions, including but not limited to, changes in pH, changes in temperature, concentration or availability of enzymes, concentration or availability of water, or other physiological conditions or compounds.
- Compositions can be prepared according to conventional mixing, granulating or coating methods, respectively, and the present compositions can comprise, in one embodiment, from about 0.1% to about 99%; and in another embodiment from about 1% to about 70% of the compounds described herein or their pharmaceutically acceptable salts by weight or volume.
- In some embodiments, low dose naltexone or other compounds described herein may be administered to a subject for a period of about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, or about 12 months, or about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10 years. In some embodiments, low dose naltexone or other compounds described herein may be administered to a subject chronically.
- In another embodiment, the compounds described herein or their pharmaceutically acceptable salts act synergistically when co-administered with another therapeutic agent and are administered at doses that are lower than the doses commonly employed when such agents are used as monotherapy. The dosage of compounds described herein or their pharmaceutically acceptable salts as well as the dosing schedule can depend on various parameters, including, but not limited to, the depression and/or mood disorder being treated, the subject's general health, and the administering physician's discretion. The compounds described herein or their pharmaceutically acceptable salts, such as, for example, naltrexone or related opioid antagonist, can be administered prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concurrently with, or subsequent to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of an additional therapeutic, such as, for example, one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRI), and a selective serotonin re-uptake inhibitor (SSRI), to a subject in need thereof. In various embodiments, the compounds described herein or their pharmaceutically acceptable salts are administered 1 minute apart, 10 minutes apart, 30 minutes apart, less than 1 hour apart, 1 hour apart, 1 hour to 2 hours apart, 2 hours to 3 hours apart, 3 hours to 4 hours apart, 4 hours to 5 hours apart, 5 hours to 6 hours apart, 6 hours to 7 hours apart, 7 hours to 8 hours apart, 8 hours to 9 hours apart, 9 hours to 10 hours apart, 10 hours to 11 hours apart, 11 hours to 12 hours apart, no more than 24 hours apart or no more than 48 hours apart.
- Methods of administration include but are not limited to oral, subcutaneous, intradermal, intramuscular (by way of non-limiting example, intramuscular depot, such as, for instance, as described in U.S. Pat. No. 6,569,449, the contents of which are hereby incorporated by reference in its entirety), intraperitoneal, intravenous, intranasal, epidural, sublingual, intranasal, intracerebral, intravaginal, transdermal, rectally, by inhalation, or topically, particularly to the ears, nose, eyes, or skin. The mode of administration can be left to the discretion of the practitioner. In most instances, administration results in the release of the compounds described herein or their pharmaceutically acceptable salts into the bloodstream.
- The compounds described herein or their pharmaceutically acceptable salts can be administered orally. The compounds described herein or their pharmaceutically acceptable salts can also be administered by any other convenient route, for example, by intravenous infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and can be administered together with another biologically active agent. Administration can be systemic or local. Various delivery systems are known, e.g., encapsulation in liposomes, microparticles, microcapsules, capsules, etc., and can be used to administer the compounds described herein or their pharmaceutically acceptable salts.
- In yet another embodiment, the compounds described herein or their pharmaceutically acceptable salts can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, 1990, Science 249:1527-1533; Sefton, 1987, CRC Crit. Ref Biomed. Eng. 14:201; Buchwald et al., 1980, Surgery 88:507; Saudek et al., 1989, N. Engl. J. Med. 321:574). In another embodiment, polymeric materials can be used (see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Fla. (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, 1983, J. Macromol. Sci. Rev. Macromol. Chem. 23:61; see also Levy et al., 1985, Science 228:190; During et al., 1989, Ann. Neurol. 25:351; Howard et al., 1989, J. Neurosurg. 71:105). Other controlled-release systems discussed in the review by Langer, 1990, Science 249:1527-1533) may be used.
- Administration of the described compounds or their pharmaceutically acceptable salts can, independently, be one to four times daily or one to four times per month or one to six times per year or once every two, three, four or five years. Administration can be for the duration of one day or one month, two months, three months, six months, one year, two years, three years, and may even be for the life of the subject. Chronic, long-term administration will be indicated in many cases. The dosage may be administered as a single dose or divided into multiple doses.
- The dosage regimen utilizing the described compounds or their pharmaceutically acceptable salts can be selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the subject; the severity of the condition to be treated; the route of administration; the renal or hepatic function of the subject; and the specific compound of the invention employed. The described compounds or their pharmaceutically acceptable salts can be administered in a single daily dose, or the total daily dosage can be administered in divided doses of two, three or four times daily. The compounds described herein or their pharmaceutically acceptable salts and/or additional therapeutic can be assayed in vitro or in vivo for the desired therapeutic or prophylactic activity prior to use in humans. Animal model systems can be used to demonstrate safety and efficacy.
- The term subject, as used herein unless otherwise defined, is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, or baboon. The terms “subject” and “patient” are used interchangeably. In some embodiments, a subject is a human suffering from a type of depression described herein who does not also suffer from alcohol or drug dependence.
- In one embodiment, the subject is a human. In some embodiments, the human is a pediatric human. In other embodiments, the subject is an adult human.
- In certain embodiments, the human has an age in a range of from about 0 months to about 6 months old, from about 6 to about 12 months old, from about 6 to about 18 months old, from about 18 to about 36 months old, from about 1 to about 5 years old, from about 5 to about 10 years old, from about 10 to about 15 years old, from about 15 to about 20 years old, from about 20 to about 25 years old, from about 25 to about 30 years old, from about 30 to about 35 years old, from about 35 to about 40 years old, from about 40 to about 45 years old, from about 45 to about 50 years old, from about 50 to about 55 years old, from about 55 to about 60 years old, from about 60 to about 65 years old, from about 65 to about 70 years old, from about 70 to about 75 years old, from about 75 to about 80 years old, from about 80 to about 85 years old, from about 85 to about 90 years old, from about 90 to about 95 years old or from about 95 to about 100 years old.
- In addition to treating pre-existing depression and/or mood disorders and/or other disorders descried herein, the described compounds or their pharmaceutically acceptable salts can be administered prophylactically in order to prevent or slow the onset of these disorders. In prophylactic applications, the described compounds or their pharmaceutically acceptable salts can be administered to a subject susceptible to or otherwise at risk of a particular depression and/or mood disorder and/or other disorders descried herein.
- In another embodiment, an outcome of the methods of the present invention is rapid antidepressant response as compared to the usual latency for response to traditional antidepressant pharmacotherapy. Such a response can be less than about 1 day, or about 2 days, or about 3 days, or about 4 days, or about 5 days, or about 6 days, or about 7 days, or about 10 days, or about 2 weeks. In some embodiments, the latency for response to traditional antidepressant pharmacotherapy is about 3, or about 4, or about 5, or about, 6 weeks, or about 8, or about 10 weeks.
- The invention also provides kits that can simplify the administration of the described compounds or their pharmaceutically acceptable salts, to a subject.
- A typical kit of the invention comprises the described compounds or their pharmaceutically acceptable salts, for example, in unit dosage form. In one embodiment, the unit dosage form is a container, which can be sterile, containing an effective amount of a described compound or their pharmaceutically acceptable salts and a pharmaceutically acceptable carrier, diluent, excipient, or vehicle. The kit can further comprise a label or printed instructions instructing the use of described compounds or their pharmaceutically acceptable salts to treat or prevent depression and/or mood disorders and/or other disorders descried herein. The kit can also further comprise one or more additional therapeutic agents, for example, in unit dosage form, such as a container containing an effective amount of the other therapeutic agent. In one embodiment, the kit comprises a container containing an effective amount of naltrexone or related opioid antagonist or a pharmaceutically acceptable salt thereof and an effective amount of another therapeutic agent. Examples of other therapeutic agents include, but are not limited to, those listed herein.
- This invention is further illustrated by the following non-limiting examples.
- Patient #1: A middle aged female suffered severe depression with recurrent major depressive episodes. She had responded briefly to complex polypharmacy and electroconvulsive therapy, but depression usually returned within 3 weeks of these interventions. In addition to restarting aripiprazole (ABILIFY), to which she had transiently responded in the past, the patient was instructed to pulverize a tablet of naltrexone 50 mg, and take the smallest fragment with water. A sample of these fragments was later weighed, indicating she was taking on the average about 1 mg of naltrexone daily. The former pharmacologic regimen was otherwise unchanged.
- About one week after initiating low dose naltrexone, the patient experienced marked remission. Despite minor variation in mood, she has maintained the remission for more than 6 months (continuing to present). She has remained on
adjunctive naltrexone 1 mg daily. - Patient #2: A particularly treatment-resistant patient with a depressive recurrence, was administered approximately 1 mg daily of naltrexone to a complex antidepressant regimen, which included duloxetine and riluzole. This patient demonstrated a robust response within 2 weeks, which has now been maintained for over 2 years.
- Patient #3: A female patient in her 50s presented with treatment-resistant depression. The patient was also diagnosed with Attention Deficit Disorder. The patient initially was treated with s-
citalopram 15 mg, augmented by dextro-amphetamine. She responded briefly but rapidly returned to depressed mood with attention deficits. Whennaltrexone 1 mg was added to her treatment regime, the patient experienced a marked lifting of mood, noting that her attention was also much improved. This response was seen within days of the addition of naltrexone. She reported no adverse effects. - Patient #4: A 62-year-old female patient weighing approximately 60 kg had suffered severe unremitting depression. She was treated with and responded to electro-convulsive therapy, but regressed within a week. Complex pharmacotherapy, including s-citalopram augmented by aripiprazole and mirtazepine, led to only transient response, with depressive symptoms returning after several days. Subsequently, the patient was prescribed 5 mg naltrexone daily with continuation of s-citalopram. The patient has remained euthymic during more than two months of observation.
- Patient #5: A female patient in her 40s had suffered severe treatment-resistant depression, exhibiting low energy, crying, unable to obtain and maintain employment, and anhedonia. She was being treated with buproprion XL 300 mg, augmented with
melatonin 3 mg and N-acetyl-cysteine 1200 mg. The patient was thenco-administered naltrexone 1 mg, and within two weeks, she experienced marked remission. After five months and continuing, she is no longer crying has improved motivation and interests, and has obtained meaningful employment. - Patient #6: A male patient in his 80s with multiple major depression episodes, anhedonia, apathy, low energy and poor sleep was being treated with duloxetine 60 mg and buproprion 75 mg, and mirtazpine 15 mg.
Naltrexone 1 mg was added, and within one week, the patient felt much better, stating that adding the naltrexone has a unique effect. The patient also reported that he had more energy, was sleeping better, was sexually active, and had returning interest in his hobby. - Patient #7: A female patient in her late 50s with a brain tumor, epilepsy and somatization disorder, also demonstrated multiple depression episodes. She rarely left her couch, lived in social isolation, often cried, did not shower or get dressed. She also called and e-mailed multiple times per day. She was being treated with Effexor XR 75 mg QHS, Xanax 0.5 mg, and Clonazepam 1.5 mg. After adding
naltrexone 1 mg, and gabapentin 300 mg andmelatonin 5 mg, within three weeks, the patient was able to obtain employment, was socializing with friends, was less anxious. Her crying episodes were replaced with smiling and laughing. - Patient #8: A treatment-resistant patient with depressive recurrence was being treated with pramipexole with limited benefit. The patient was then co-administered 1 mg daily of naltrexone with pramipexole. The patient demonstrated a robust response within a few weeks.
- Patient #9: A middle-age female suffered severe depression with recurrent major depressive episodes and social anxiety. She was being treated with
Adderall 10 mg, levothyroxine 50 mcg, and propranol 10 mg.Naltrexone 1 mg was added to her regimen, and she experienced improvement in her depression. - The clinical studies described herein, in part, assess the magnitude and rate of response to low dose naltrexone, as measured by change on the Hamilton Rating Scale for Depression (HAM-D-17 or HAM-D-28), compared to placebo. Additional assessments are based on the Montgomery-Asberg Depression Rating Scale (MADRS-10 or MADRS-15) and Clinical Global Impressions-Severity and Improvement (CGI-S and CGI-I).
- The trial was conducted over 6 weeks, with double-blind treatment based on random assignment to low dose naltrexone or placebo. To assess longevity of response to Low Dose Naltrexone, patients assigned to active drug were followed for 6 weeks, but the design did not provide a contrasting placebo group beyond 3 weeks.
- 12 men and
women ages 25 to 64 who received antidepressant regimens including at least one dopaminergic agent (an NDRI, pramipexole, aripiperazole at less than or equal to 2 mg, amphetamine salt, methylphenidate, or sertraline at 150 mg or greater), had achieved remission for at least 3 months followed by relapse or recurrence, were recruited. All ethnicities were included. - Inclusion criteria included an age of 18-65; written informed consent; patients meet DSM-IV criteria (by Structured Clinical Interview for DSM-IV SCID-I/P) for MDD, current; Quick Inventory of Depressive Symptomatology-Self-Rated (QIDS-SR) score of at least 12 at both screen and baseline visits; received treatment with SSRI in combination with a dopaminergic agent; or on an antidepressant with a dopaminergic mechanism of action, including SNRIs, MAOIs, TCAs, or bupropion, in adequate doses, achieved remission per ACNP Task Force guidelines (REF) for ≥3 months, currently in relapse or recurrence without dose change for at least the past 4 weeks, based on meeting DSM-IV criteria for MDD.
- Dopaminergic agents here included, for example, classical stimulants from the amphetamine or methylphenidate families; the wakefulness promoting agents, modafinil and armodafinil; dopamine agonists (e.g. pramipexole); or bupropion (≥300 mg/day to ensure significant dopamine reuptake inhibition). Additionally, low dose (≤2.5 mg) Abilify, a D2 partial agonist, was included as a dopamine agent. Sertraline, classified as an SSRI, had dopamine reuptake inhibiting properties believed to be relevant at higher doses (≥150 mg) and was therefore considered a dopaminergic agent, as well as allowed as SSRI monotherapy at dopaminergic doses. SNRIs (e.g. venlafaxine) and TCAs (e.g. nortriptyline) were known to have prominent inhibitory effects on the reuptake of norepinephrine; however, since the norepinephrine transporter was responsible for both norepinephrine and dopamine reuptake in the prefrontal cortex, these agents were also considered to be pro-dopaminergic antidepressants.
- During the baseline visit, patients were on a stable dose of antidepressant regimen for the past 4 weeks.
- Once patients agreed to participate in the study by signing the informed consent document, a full medical and psychiatric history was taken and a physical examination was performed by a board-certified psychiatrist. Screen rating scales were performed. Screened and eligible patients were asked to return one week later for a baseline visit when they are randomized to double-blind treatment with placebo or low dose naltrexone, with the study design outlined above. The study lasted six weeks, during which patients were assessed weekly. Subjects were assigned randomization numbers in consecutive order. The randomization list was provided by a computer-generated random-number list and was maintained by the research pharmacist. In addition, the presence of any side effect or adverse event was carefully documented with the SAFTEE-SI. Reasons for premature discontinuation, including change in primary medications, were recorded.
- All concomitant medications taken during the study were recorded in the case report form, along with dosage information and start and stop dates. Medication management and clinical ratings were performed by the study clinicians.
- At the end of the double-blind study, both responders and non-responders who completed the double-blind phase had the option of receiving open-label adjunctive treatment with low dose naltrexone. Subjects who agreed to receive open-label treatment with low dose naltrexone for 3 months were seen monthly by a board-certified psychiatrist until the end of the follow-up phase. Subjects who completed or refused follow-up were offered a referral to a psychiatrist.
- The primary efficacy measurement was the change in 17-item Hamilton Rating Scale for Depression (HAM-D-17) score or the 28-item Hamilton Rating Scale for Depression (HAM-D-28). Secondary measures of efficacy include change in CGI-severity, with clinical or CGI-improvement (CGI-I). An additional measure of efficacy was the change in Montgomery-Asberg Depression Rating Scale (MADRS-10 or MADRS-15).
- The following instruments were administered according to the study schedule: a structured clinical interview for DSM-IV, an antidepressant treatment history questionnaire, the 17-item or 28-item Hamilton Depression Scale (HAM-D-17 or HAM-D-28), Clinical Global Impressions-severity and improvement (CGI-S, CGI-I), 10-item or 15-item Montgomery-Asberg Depression Rating Scale (MADRS-10 or MADRS-15), Quick inventory Depressive Symptomatology (Self Report) (QIDS-SR), a cognitive and physical functioning questionnaire, a sexual functioning questionnaire, the Quality of Life Satisfaction Questionnaire-short form (Q-LES-Q), and the Sheehan Disability Scale.
- Low dose naltrexone showed specific efficacy for the treatment of “breakthrough depression,” an umbrella term, which encompasses depressive relapse (a depressive episode within 6 months of antidepressant response) and recurrence (a depressive episode after 6 months of response). Patients with breakthrough depression (BTD) on an antidepressant regimen containing a pro-dopaminergic agent assigned to treatment with low dose naltrexone (1 mg bid) demonstrated higher rates of response on all outcome measures. See figures for statistical analysis (e.g.
FIGS. 1A, 2A, 3A, 4A, 5A, and 6A ). The response to active drug continued during the entire six week trial period (e.g.FIGS. 1B, 2B, 3B, 4B, 5B, and 6B ). - Additionally, patients with BTD on an antidepressant regimen containing a pro-dopaminergic agent assigned to treatment with low dose naltrexone experienced no significant differences in the number of adverse events, as measured by the SAFTEE-SI as well as greater improvement in Quality of Life, Enjoyment, and Satisfaction Questionnaire (Q-LES-Q) and Sheehan Disability Scale (SDS) scores, compared to placebo controls.
- Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific embodiments described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.
- All patents and publications referenced herein are hereby incorporated by reference in their entireties.
Claims (90)
1. A method of treating or preventing breakthrough depression, comprising administering a therapeutically effective low dose amount of naltrexone to a patient in need thereof.
2. The method of claim 1 , wherein the therapeutically effective low dose amount of naltrexone is administered in conjunction with a patient's pre-existent anti-depression treatment,
wherein the pre-existent anti-depression treatment comprises one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRI), and a selective serotonin re-uptake inhibitor (SSRI).
3. The method of claim 1 or 2 , wherein breakthrough depression comprises depressive relapse and/or recurrence.
4. The method of claims 1 -3 , wherein the therapeutically effective low dose amount of naltrexone is administered at doses that reverse or prevent desensitization of a dopamine receptor.
5. The method of claim 4 , wherein the dopamine receptor is one or more of the D2 and D3 receptors.
6. The method of claims 1 -5 , wherein the therapeutically effective low dose amount of naltrexone is administered at doses that are substantially below levels that induce significant opioid blockade.
7. The method of claim 4 or 6 , wherein the amount of naltrexone administered is less than 10 mg.
8. The method of claim 4 or 6 , wherein the amount of naltrexone administered is about 1-4 mg.
9. The method of claim 4 or 6 , wherein the amount of naltrexone administered is about 1 mg.
10. The method of claims 2 -9 , wherein the dopamine active anti-depressant agent is one or more of bupropion, aripiprazole, and sertraline.
11. The method of claim 2 -9 , wherein the SNRI is selected from duloxetine, venlafaxine, nefazodone, and milnacipran.
12. The method of claim 2 -9 , wherein the dopamine active augmenting agent is one or more of an amphetamine salt, pramipexole, and ropinirole.
13. The method of claim 2 -9 , wherein the SSRI is selected from citalopram, dapoxetine, s-citalopram, fluoxetine, fluvoxamine, indalpine, paroxetine, and zimelidine.
14. The method of any of the above claims, wherein the preventing or treating breakthrough depression comprises reduction in length of a depressive episode.
15. The method of any of the above claims, wherein the preventing or treating breakthrough depression comprises recovery of an anti-depressive effect of the patient's pre-existent anti-depression treatment regimen.
16. The method of any of the above claims, wherein the preventing or treating breakthrough depression comprises a reduction in the rate of relapse after major depressive episodes.
17. The method of any of the above claims, wherein the preventing or treating breakthrough depression comprises prevention or reversal of loss of efficacy of the patient's pre-existent anti-depression treatment.
18. The method of any of the above claims, wherein the preventing or treating breakthrough depression comprises reduction in an effective dosage of the patient's pre-existent anti-depression treatment.
19. The method of claim 18 , wherein the reduction in an effective dosage of the patient's pre-existent anti-depression treatment causes one or more of a reduction in side effects and increase in patient adherence.
20. The method of any of the above claims, wherein the therapeutically effective low dose amount of naltrexone is administered orally or subcutaneously.
21. A method of preventing or treating treatment-refractory depression, comprising administering a therapeutically effective low dose amount of naltrexone to a patient in need thereof.
22. The method of claim 21 , wherein the therapeutically effective low dose amount of naltrexone is administered in conjunction with a patient's pre-existent anti-depression treatment, wherein the pre-existent anti-depression treatment comprises one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRI), and a selective serotonin re-uptake inhibitor (SSRI).
23. The method of claim 21 or 22 , wherein treatment-refractory depression comprises depressive relapse and/or recurrence.
24. The method of claims 21 -23 , wherein the therapeutically effective low dose amount of naltrexone is administered at doses that reverse or prevent desensitization of a dopamine receptor.
25. The method of claim 24 , wherein the dopamine receptor is one or more of the D2 and D3 receptors.
26. The method of claims 21 -25 , wherein the therapeutically effective low dose amount of naltrexone is administered at doses that are substantially below levels that induce significant opioid blockade.
27. The method of claim 24 or 26 , wherein the amount of naltrexone administered is less than 10 mg.
28. The method of claim 24 or 26 , wherein the amount of naltrexone administered is about 1-4 mg.
29. The method of claim 24 or 26 , wherein the amount of naltrexone administered is about 1 mg.
30. The method of claim 22 -29 , wherein the dopamine active anti-depressant agent is one or more of bupropion, aripiprazole, and sertraline.
31. The method of claim 22 -29 , wherein the SNRT is selected from duloxetine, venlafaxine, nefazodone, and milnacipran.
32. The method of claim 22 -29 , wherein the dopamine active augmenting agent is one or more of an amphetamine salt, pramipexole, and ropinirole.
33. The method of claim 22 -29 , wherein the SSRI is selected from citalopram, dapoxetine, s-citalopram, fluoxetine, fluvoxamine, indalpine, paroxetine, and zimelidine.
34. The method of any of the above claims, wherein the preventing or treating treatment-refractory depression comprises reduction in length of a depressive episode.
35. The method of any of the above claims, wherein the preventing or treating treatment-refractory depression comprises recovery of an anti-depressive effect of the patient's pre-existent anti-depression treatment regimen.
36. The method of any of the above claims, wherein the preventing or treating treatment-refractory depression comprises a reduction in the rate of relapse after major depressive episodes.
37. The method of any of the above claims, wherein the preventing or treating treatment-refractory depression comprises prevention or reversal of loss of efficacy of the patient's pre-existent anti-depression treatment.
38. The method of any of the above claims, wherein the wherein the preventing or treating treatment-refractory depression comprises reduction in an effective dosage of the patient's pre-existent anti-depression treatment.
39. The method of claim 38 , wherein the reduction in an effective dosage of the patient's pre-existent anti-depression treatment causes one or more of a reduction in side effects and increase in patient adherence.
40. The method of any of the above claims, wherein the effective amount of low dose naltrexone is administered orally or subcutaneously.
41. A method of preventing or treating breakthrough depression, comprising administering a combination of a therapeutically effective low dose amount of naltrexone and a therapeutically effective amount of one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRI), and a selective serotonin re-uptake inhibitor (SSRI) to a patient in need thereof.
42. The method of claim 41 , wherein the combination is administered in conjunction with a patient's pre-existent anti-depression treatment, wherein the pre-existent anti-depression treatment comprises one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRT), and a selective serotonin re-uptake inhibitors (SSRI).
43. The method of claim 41 or 42 , wherein breakthrough depression comprises depressive relapse and/or recurrence.
44. The method of claims 41 -43 , wherein the low dose naltrexone is administered at doses that reverse or prevent desensitization of a dopamine receptor.
45. The method of claim 44 , wherein the dopamine receptor is one or more of the D2 and D3 receptors.
46. The method of claims 41 -45 , wherein the therapeutically effective low dose amount of naltrexone is administered is administered at doses that are substantially below levels that induce significant opioid blockade.
47. The method of claim 44 or 46 , wherein the amount of naltrexone administered is less than 10 mg.
48. The method of claim 44 or 46 , wherein the amount of naltrexone administered is about 1-4 mg.
49. The method of claim 44 or 46 , wherein the amount of naltrexone administered is about 1 mg.
50. The method of claims 41 -49 , wherein the dopamine active anti-depressant agent is one or more of bupropion, aripiprazole, and sertraline.
51. The method of claim 41 -49 , wherein the SNRT is selected from duloxetine, venlafaxine, nefazodone, and milnacipran.
52. The method of claims 41 -49 , wherein the dopamine active augmenting agent is one or more of an amphetamine salt, pramipexole, and ropinirole.
53. The method of claims 41 -49 , wherein the SSRI is selected from citalopram, dapoxetine, s-citalopram, fluoxetine, fluvoxamine, indalpine, paroxetine, and zimelidine.
54. The method of claims 41 -49 , wherein the preventing or treating breakthrough depression comprises reduction in length of a depressive episode.
55. The method of claims 41 -49 , wherein the preventing or treating breakthrough depression comprises recovery of the anti-depressive effect of the patient's pre-existent anti-depression treatment regimen.
56. The method of any of the above claims, wherein the preventing or treating breakthrough depression comprises a reduction in the rate of relapse after major depressive episodes.
57. The method of any of the above claims, wherein the preventing or treating breakthrough depression comprises prevention or reversal of loss of efficacy of the patient's pre-existent anti-depression treatment.
58. The method of any of the above claims, wherein the wherein the preventing or treating breakthrough depression comprises reduction in an effective dosage of the patient's pre-existent anti-depression treatment.
59. The method of claim 58 , wherein the reduction in an effective dosage of the patient's pre-existent anti-depression treatment causes one or more of a reduction in side effects and increase in patient adherence.
60. The method of any of the above claims wherein the effective amount of low dose naltrexone is administered orally or subcutaneously.
61. The method of claims 41 -60 , wherein the naltrexone and one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRI), and a selective serotonin re-uptake inhibitors (SSRI) are co-formulated in a single dosage form.
62. The method of claim 41 , wherein the dosage form is an oral dosage form.
63. The method of claim 41 , wherein the dosage form is a subcutaneous dosage form.
64. A method of preventing or treating treatment-refractory depression, comprising administering a combination of a therapeutically effective low dose amount of naltrexone and a therapeutically effective amount of one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRT), and a selective serotonin re-uptake inhibitor (SSRI) to a patient in need thereof.
65. The method of claim 64 , wherein the combination is administered in conjunction with a patient's pre-existent anti-depression treatment, wherein the pre-existent anti-depression treatment comprises one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRT), and a selective serotonin re-uptake inhibitors (SSRI).
66. The method of claim 64 or 65 , wherein treatment-refractory depression comprises depressive relapse and/or recurrence.
67. The method of claims 64 -66 , wherein the low dose naltrexone is administered at doses that reverse or prevent desensitization of a dopamine receptor.
68. The method of claim 67 , wherein the dopamine receptor is one or more of the D2 and D3 receptors.
69. The method of claims 64 -68 , wherein the low dose naltrexone is administered at doses that are substantially below levels that induce significant opioid blockade.
70. The method of claim 67 or 69 , wherein the amount of naltrexone administered is less than 10 mg.
71. The method of claim 67 or 69 , wherein the amount of naltrexone administered is about 1-4 mg.
72. The method of claim 67 or 69 , wherein the amount of naltrexone administered is about 1 mg.
73. The method of claims 64 -72 , wherein the dopamine active anti-depressant agent is one or more of bupropion, aripiprazole, and sertraline.
74. The method of claim 64 -73 , wherein the SNRT is selected from duloxetine, venlafaxine, nefazodone, and milnacipran.
75. The method of claims 64 -73 , wherein the dopamine active augmenting agent is one or more of an amphetamine salt, pramipexole, and ropinirole.
76. The method of claims 64 -73 , wherein the SSRI is selected from citalopram, dapoxetine, s-citalopram, fluoxetine, fluvoxamine, indalpine, paroxetine, and zimelidine.
77. The method of claims 64 -73 , wherein the preventing or treating treatment-refractory depression comprises reduction in length of a depressive episode.
78. The method of claims 64 -73 , wherein the preventing or treating treatment-refractory depression comprises recovery of the anti-depressive effect of the patient's pre-existent anti-depression treatment regimen.
79. The method of claims 64 -73 , wherein the preventing or treating treatment-refractory depression comprises a reduction in the rate of relapse after major depressive episodes.
80. The method of claims 64 -73 , wherein the preventing or treating treatment-refractory depression comprises prevention or reversal of loss of efficacy of the patient's pre-existent anti-depression treatment.
81. The method of claims 64 -73 , wherein the wherein the preventing or treating treatment-refractory depression comprises reduction in an effective dosage of the patient's pre-existent anti-depression treatment.
82. The method of claim 81 , wherein the reduction in an effective dosage of the patient's pre-existent anti-depression treatment causes one or more of a reduction in side effects and increase in patient adherence.
83. The method of claim 64 or 65 , wherein the effective amount of low dose naltrexone is administered orally.
84. The method of claim 64 or 65 , wherein the naltrexone and one or more of a dopamine active anti-depressant agent, a dopamine active augmenting agent, a serotonin-norepinephrine reuptake inhibitor (SNRI), and a selective serotonin re-uptake inhibitors (SSRI) are co-formulated in a single dosage form.
85. The method of claim 64 , wherein the dosage form is an oral dosage form.
86. The method of claim 64 , wherein the dosage form is a subcutaneous dosage form.
87. The methods of claim 64 or 65 , where the outcome is rapid antidepressant response compared to the usual latency for response to traditional antidepressant pharmacotherapy.
88. The method of claim 87 , wherein the rapid antidepressant response is less than about 10 days.
89. The method of claim 87 , wherein the usual latency for response to traditional antidepressant pharmacotherapy is about 3-6 weeks.
90. A method of treating breakthrough depression, comprising administering a therapeutically effective low dose amount of naltrexone to a patient in need thereof, wherein:
the patient is on an antidepressant regimen comprising a pro-dopaminergic agent and
the therapeutically effective low dose amount of naltrexone is about 1 mg bid.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/031,662 US20180318289A1 (en) | 2013-01-30 | 2018-07-10 | Treatments for depression and other diseases with a low dose agent |
US16/379,042 US20190231772A1 (en) | 2013-01-30 | 2019-04-09 | Treatments for depression and other diseases with a low dose agent |
US16/519,638 US20190343829A1 (en) | 2013-01-30 | 2019-07-23 | Treatments for depression and other diseases with a low dose agent |
US16/810,188 US20200197388A1 (en) | 2013-01-30 | 2020-03-05 | Treatments for depression and other diseases with a low dose agent |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361758551P | 2013-01-30 | 2013-01-30 | |
US201361814476P | 2013-04-22 | 2013-04-22 | |
PCT/US2014/013874 WO2014120936A2 (en) | 2013-01-30 | 2014-01-30 | Treatments for depression and other diseases with a low dose agent |
US14/410,551 US20150342946A1 (en) | 2013-01-30 | 2014-01-30 | Treatments For Depression And Other Diseases With A Low Dose Agent |
US14/639,797 US9278094B2 (en) | 2013-01-30 | 2015-03-05 | Treatments for depression and other diseases with a low dose agent |
US15/009,415 US20160310484A1 (en) | 2013-01-30 | 2016-01-28 | Treatments for depression and other diseases with a low dose agent |
US16/031,662 US20180318289A1 (en) | 2013-01-30 | 2018-07-10 | Treatments for depression and other diseases with a low dose agent |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/009,415 Continuation US20160310484A1 (en) | 2013-01-30 | 2016-01-28 | Treatments for depression and other diseases with a low dose agent |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US201916287098A Continuation | 2013-01-30 | 2019-02-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180318289A1 true US20180318289A1 (en) | 2018-11-08 |
Family
ID=51263114
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/410,551 Abandoned US20150342946A1 (en) | 2013-01-30 | 2014-01-30 | Treatments For Depression And Other Diseases With A Low Dose Agent |
US14/639,797 Active US9278094B2 (en) | 2013-01-30 | 2015-03-05 | Treatments for depression and other diseases with a low dose agent |
US15/009,415 Abandoned US20160310484A1 (en) | 2013-01-30 | 2016-01-28 | Treatments for depression and other diseases with a low dose agent |
US16/031,662 Abandoned US20180318289A1 (en) | 2013-01-30 | 2018-07-10 | Treatments for depression and other diseases with a low dose agent |
US16/379,042 Abandoned US20190231772A1 (en) | 2013-01-30 | 2019-04-09 | Treatments for depression and other diseases with a low dose agent |
US16/519,638 Abandoned US20190343829A1 (en) | 2013-01-30 | 2019-07-23 | Treatments for depression and other diseases with a low dose agent |
US16/810,188 Abandoned US20200197388A1 (en) | 2013-01-30 | 2020-03-05 | Treatments for depression and other diseases with a low dose agent |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/410,551 Abandoned US20150342946A1 (en) | 2013-01-30 | 2014-01-30 | Treatments For Depression And Other Diseases With A Low Dose Agent |
US14/639,797 Active US9278094B2 (en) | 2013-01-30 | 2015-03-05 | Treatments for depression and other diseases with a low dose agent |
US15/009,415 Abandoned US20160310484A1 (en) | 2013-01-30 | 2016-01-28 | Treatments for depression and other diseases with a low dose agent |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/379,042 Abandoned US20190231772A1 (en) | 2013-01-30 | 2019-04-09 | Treatments for depression and other diseases with a low dose agent |
US16/519,638 Abandoned US20190343829A1 (en) | 2013-01-30 | 2019-07-23 | Treatments for depression and other diseases with a low dose agent |
US16/810,188 Abandoned US20200197388A1 (en) | 2013-01-30 | 2020-03-05 | Treatments for depression and other diseases with a low dose agent |
Country Status (7)
Country | Link |
---|---|
US (7) | US20150342946A1 (en) |
EP (1) | EP2950799B1 (en) |
JP (1) | JP6406713B2 (en) |
CN (1) | CN104955483A (en) |
CA (1) | CA2899455C (en) |
HK (1) | HK1212254A1 (en) |
WO (1) | WO2014120936A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020146412A1 (en) * | 2019-01-07 | 2020-07-16 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
RU2679661C1 (en) * | 2013-12-20 | 2019-02-12 | Х. Лундбекк А/С | Use of opioid receptor antagonist with k-activity and vortioxetine for treatment of depressive disorder with melancholic features |
US20170042887A1 (en) * | 2014-04-22 | 2017-02-16 | Otsuka Pharmaceutical. Co., Ltd. | Combination of Brexpiprazole and Nalmefene and Use Thereof for Treating Substance-Related Disorders |
US9616068B2 (en) * | 2014-10-27 | 2017-04-11 | Pohela LLC | Animal training using cognitive enhancement |
EP3416619A2 (en) * | 2016-02-18 | 2018-12-26 | Immune Therapeutics, Inc. | Method for inducing a sustained immune response |
CA3061340A1 (en) | 2017-04-25 | 2018-11-01 | Temple Otorongo Llc | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions |
CA3145388A1 (en) | 2019-07-19 | 2021-01-28 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
JP2024501919A (en) * | 2020-11-27 | 2024-01-17 | トレクサファーム・プロプライエタリー・リミテッド | Compositions containing flumazenil and naltrexone and methods of use thereof |
WO2023278824A1 (en) * | 2021-07-02 | 2023-01-05 | Bioxcel Therapeutics, Inc. | Methods for treating depressive states |
US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (en) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5028612A (en) | 1990-03-22 | 1991-07-02 | Hillel Glover | Method for treating emotional numbness |
US5817656A (en) | 1991-04-23 | 1998-10-06 | Eli Lilly And Company | Mental disorders |
US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
USRE36547E (en) | 1992-09-21 | 2000-02-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US5512593A (en) * | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
IT1270594B (en) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN |
EP0782445B1 (en) | 1994-09-19 | 2002-03-13 | Dupont Pharmaceuticals Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
DE69632235T2 (en) | 1995-10-18 | 2004-08-26 | Akzo Nobel N.V. | Newcastle disease viral vaccines combined |
US6001848A (en) | 1996-03-25 | 1999-12-14 | The Regents Of The University Of California | Bromocriptine for the treatment of alcoholics diagnosed with the D2 dopamine receptor DRD2 A1 allele |
GB9700878D0 (en) | 1997-01-17 | 1997-03-05 | Scherer Ltd R P | Dosage forms and method for ameliorating male erectile dysfunction |
US6001861A (en) | 1998-01-16 | 1999-12-14 | Pharmacia & Upjohn Company | Use of pramipexole in the treatment of restless legs syndrome |
WO1998052565A1 (en) | 1997-05-20 | 1998-11-26 | Yale University | Substance dependence treatment using opiate antagonists and serotonin compounds |
GB9815618D0 (en) | 1998-07-18 | 1998-09-16 | Univ Manchester | Treatment of dyskinesia |
US6765010B2 (en) | 1999-05-06 | 2004-07-20 | Pain Therapeutics, Inc. | Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
AR031682A1 (en) | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | PHARMACEUTICAL COMPOSITIONS |
AU2001294808A1 (en) | 2000-09-29 | 2002-04-08 | Board Of Trustees Operating Michigan State University | Catecholamine pharmaceutical compositions and methods |
AR031152A1 (en) | 2000-10-31 | 2003-09-10 | Upjohn Co | NEW TREATMENTS FOR THE CONCERNED LEG SYNDROME |
US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
US20030087896A1 (en) | 2001-08-09 | 2003-05-08 | Hillel Glover | Treatment of refractory depression with an opiate antagonist and an antidepressant |
US20050037983A1 (en) | 2003-03-11 | 2005-02-17 | Timothy Dinan | Compositions and methods for the treatment of depression and other affective disorders |
EP1870096A3 (en) | 2003-04-29 | 2011-04-20 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
US20050245541A1 (en) | 2004-03-19 | 2005-11-03 | Elliot Ehrich | Methods for treating alcoholism |
WO2005112931A2 (en) | 2004-05-12 | 2005-12-01 | The Government Of The United States As Represented By The Secretary, Department Of Health And Human Services | Methods related to the treatment of neurodegenerative and inflammatory conditions |
JP2008514612A (en) * | 2004-09-23 | 2008-05-08 | ミシャロウ、アレクサンダー | Methods of modulating neurotransmitter systems by inducing counter adaptation |
US20080045610A1 (en) | 2004-09-23 | 2008-02-21 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
US20070099947A1 (en) | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
EP1951212A2 (en) | 2005-11-22 | 2008-08-06 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
AR058239A1 (en) | 2005-11-28 | 2008-01-23 | Orexigen Therapeutics Inc | METHODS TO TREAT ANXIETY DISORDERS |
EP2001495A4 (en) | 2006-02-27 | 2010-12-08 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
US20070232638A1 (en) | 2006-04-03 | 2007-10-04 | Howard Brooks-Korn | Opiopathies |
CA2649881A1 (en) | 2006-04-19 | 2007-11-01 | Jill P. Smith | Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists |
US20070259939A1 (en) | 2006-05-04 | 2007-11-08 | Accelerated Technologies | Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness |
EP2029136A4 (en) | 2006-05-22 | 2010-01-06 | Vanda Pharmaceuticals Inc | Treatment for depressive disorders |
US20100203084A1 (en) | 2006-11-01 | 2010-08-12 | Crain Stanley M | Method for treating pain or opioid dependence using a specific type of non-opioid agent in combination with a selective excitatory-opioid-receptor inactivator |
CA2697990A1 (en) * | 2007-08-27 | 2009-03-05 | University Of Virginia Patent Foundation | Medication combinations for the treatment of alcoholism and drug addiction |
US20100168119A1 (en) * | 2008-11-05 | 2010-07-01 | Pharmorx, Inc. | Compositions and methods for minimizing or reducing agonist-induced desensitization |
WO2011119227A2 (en) | 2010-03-25 | 2011-09-29 | Columbia Northwest Pharmaceuticals, Llc | Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients |
WO2012104852A1 (en) | 2011-01-31 | 2012-08-09 | Serotech, Llc | Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder |
WO2012118562A1 (en) | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
-
2014
- 2014-01-30 JP JP2015555445A patent/JP6406713B2/en not_active Expired - Fee Related
- 2014-01-30 WO PCT/US2014/013874 patent/WO2014120936A2/en active Application Filing
- 2014-01-30 EP EP14746250.1A patent/EP2950799B1/en active Active
- 2014-01-30 CA CA2899455A patent/CA2899455C/en active Active
- 2014-01-30 US US14/410,551 patent/US20150342946A1/en not_active Abandoned
- 2014-01-30 CN CN201480006714.1A patent/CN104955483A/en active Pending
-
2015
- 2015-03-05 US US14/639,797 patent/US9278094B2/en active Active
-
2016
- 2016-01-14 HK HK16100404.2A patent/HK1212254A1/en unknown
- 2016-01-28 US US15/009,415 patent/US20160310484A1/en not_active Abandoned
-
2018
- 2018-07-10 US US16/031,662 patent/US20180318289A1/en not_active Abandoned
-
2019
- 2019-04-09 US US16/379,042 patent/US20190231772A1/en not_active Abandoned
- 2019-07-23 US US16/519,638 patent/US20190343829A1/en not_active Abandoned
-
2020
- 2020-03-05 US US16/810,188 patent/US20200197388A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2016506933A (en) | 2016-03-07 |
US9278094B2 (en) | 2016-03-08 |
US20200197388A1 (en) | 2020-06-25 |
CA2899455C (en) | 2021-06-08 |
US20150342946A1 (en) | 2015-12-03 |
JP6406713B2 (en) | 2018-10-17 |
US20190343829A1 (en) | 2019-11-14 |
EP2950799B1 (en) | 2019-12-04 |
CA2899455A1 (en) | 2014-08-07 |
EP2950799A4 (en) | 2016-09-21 |
WO2014120936A3 (en) | 2014-10-16 |
US20150202199A1 (en) | 2015-07-23 |
US20190231772A1 (en) | 2019-08-01 |
WO2014120936A2 (en) | 2014-08-07 |
CN104955483A (en) | 2015-09-30 |
US20160310484A1 (en) | 2016-10-27 |
HK1212254A1 (en) | 2016-06-10 |
EP2950799A2 (en) | 2015-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200197388A1 (en) | Treatments for depression and other diseases with a low dose agent | |
RU2445973C2 (en) | Method of treating major depression in human | |
US20090306137A1 (en) | Treatment for depressive disorders | |
JP2009500421A (en) | Combination of eszopiclone and antidepressant | |
US20240074993A1 (en) | Methods of treating or preventing an attention disorder, cognitive disorder, and/or dementia associated with a neurodegenerative disorder | |
CN115734785A (en) | (S) - (4, 5-dihydro-7H-thieno [2,3-c ] pyran-7-yl) -N-methylmethanamine for the treatment of neurological and psychiatric disorders | |
KR20050012284A (en) | Combination therapy wherein a serotonin reuptake inhibitor is used | |
PT1628652E (en) | Combination of the analeptic modafinil and an antidepressant for the treatment of depression | |
MXPA06002504A (en) | The combination of a serotonin reuptake inhibitor and loxapine. | |
JP7312286B2 (en) | Benzoic acid or its salts and derivatives for preventing or treating depression | |
US20070042014A1 (en) | Combination of a serotonin reuptake inhibitor and loxapine | |
Roller et al. | Disease state management: Depression and antidepressants | |
Roller et al. | Disease state management: Mood disorders: Part one: Depression and antidepressants | |
US20080167290A1 (en) | Combination of a Serotonin Reuptake Inhibitor and Amoxapine | |
KR20060072126A (en) | The combination of a serotonin reuptake inhibitor and amoxapine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- INCOMPLETE APPLICATION (PRE-EXAMINATION) |